{
    "abstract": "This observer-blind study (clinicaltrials.gov NCT01462357) compared the immunogenicity and safety of two doses (2D) of the HPV-16/18 AS04-adjuvanted vaccine (2D of AS04-HPV-16/18) vs. two or three doses of the 4vHPV vaccine [2D or 3D of 4vHPV] in 1075 healthy girls aged 9\u201314 years. Girls were randomized (1:1:1) to receive 2D of AS04-HPV-16/18 at months (M) 0, 6 (N = 359), 2D of 4vHPV at M0, 6 (N = 358) or 3D of 4vHPV at M0, 2, 6 (N = 358). 351, 339 and 346 girls, respectively, returned for the concluding visit at M36. Superiority was demonstrated at M7 and M12; comparison of the immune response to both vaccine antigens was made between 2D of AS04-HPV-16/18 and 2D or 3D of 4vHPV at subsequent time points in the according-to-protocol immunogenicity cohort (ATP-I; N = 958 at M36) and the total vaccinated cohort (TVC: N = 1036 at M36). HPV-16/18-specific T-cell- and B-cell-mediated immune responses and safety were also investigated. At M36, anti-HPV-16/18 ELISA responses in the 2D AS04-HPV-16/18 group remained superior to those of the 2D and 3D 4vHPV groups. In the M36 TVC, geometric mean titers were 2.78-fold (HPV-16) and 6.84-fold (HPV-18) higher for 2D of AS04-HPV-16/18 vs. 2D of 4vHPV and 2.3-fold (HPV-16) and 4.14-fold (HPV-18) higher vs. 3D of 4vHPV. Results were confirmed by vaccine pseudovirion-based neutralisation assay. Numbers of circulating CD4+ T cells and B cells appeared similar across groups. Safety was in line with the known safety profiles of both vaccines. In conclusion, superior HPV-16/18 antibody responses were elicited by 2D of the AS04-HPV-16/18 compared with 2D or 3D of the 4vHPV vaccine in girls aged 9\u201314 years. Clinical Trial Registration: NCT0146235.",
    "author_highlights": [
        {
            "endOffset": 17741,
            "sentence": "HPV vaccines were first licensed with 3-dose schedules and can now be administered as 2 doses in young adolescents.",
            "startOffset": 17626
        },
        {
            "endOffset": 17825,
            "sentence": "We showed immunological superiority of 2D of AS04-HPV-16/18v vs. 2D or 3D of 4vHPV.",
            "startOffset": 17742
        },
        {
            "endOffset": 17909,
            "sentence": "Higher circulating antibodies may be indicative of a longer duration of protection.",
            "startOffset": 17826
        },
        {
            "endOffset": 17987,
            "sentence": "2D of AS04-HPV-16/18v safety is in line with known profiles of both vaccines.",
            "startOffset": 17910
        }
    ],
    "bib_entries": {
        "b0005": null,
        "b0010": {
            "authors": [
                {
                    "first": "Silvia",
                    "initial": "S.",
                    "last": "de Sanjose"
                },
                {
                    "first": "Wim G.V.",
                    "initial": "W.G.V.",
                    "last": "Quint"
                },
                {
                    "first": "Laia",
                    "initial": "L.",
                    "last": "Alemany"
                },
                {
                    "first": "Daan T.",
                    "initial": "D.T.",
                    "last": "Geraets"
                },
                {
                    "first": "Jo Ellen",
                    "initial": "J.E.",
                    "last": "Klaustermeier"
                },
                {
                    "first": "Belen",
                    "initial": "B.",
                    "last": "Lloveras"
                },
                {
                    "first": "Sara",
                    "initial": "S.",
                    "last": "Tous"
                },
                {
                    "first": "Ana",
                    "initial": "A.",
                    "last": "Felix"
                },
                {
                    "first": "Luis Eduardo",
                    "initial": "L.E.",
                    "last": "Bravo"
                },
                {
                    "first": "Hai Rim",
                    "initial": "H.R.",
                    "last": "Shin"
                },
                {
                    "first": "Carlos S.",
                    "initial": "C.S.",
                    "last": "Vallejos"
                },
                {
                    "first": "Patricia Alonso",
                    "initial": "P.A.",
                    "last": "de Ruiz"
                },
                {
                    "first": "Marcus Aurelho",
                    "initial": "M.A.",
                    "last": "Lima"
                },
                {
                    "first": "Nuria",
                    "initial": "N.",
                    "last": "Guimera"
                },
                {
                    "first": "Omar",
                    "initial": "O.",
                    "last": "Clavero"
                },
                {
                    "first": "Maria",
                    "initial": "M.",
                    "last": "Alejo"
                },
                {
                    "first": "Antonio",
                    "initial": "A.",
                    "last": "Llombart-Bosch"
                },
                {
                    "first": "Chou",
                    "initial": "C.",
                    "last": "Cheng-Yang"
                },
                {
                    "first": "Silvio Alejandro",
                    "initial": "S.A.",
                    "last": "Tatti"
                },
                {
                    "first": "Elena",
                    "initial": "E.",
                    "last": "Kasamatsu"
                },
                {
                    "first": "Ermina",
                    "initial": "E.",
                    "last": "Iljazovic"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Odida"
                },
                {
                    "first": "Rodrigo",
                    "initial": "R.",
                    "last": "Prado"
                },
                {
                    "first": "Muhieddine",
                    "initial": "M.",
                    "last": "Seoud"
                },
                {
                    "first": "Magdalena",
                    "initial": "M.",
                    "last": "Grce"
                },
                {
                    "first": "Alp",
                    "initial": "A.",
                    "last": "Usubutun"
                },
                {
                    "first": "Asha",
                    "initial": "A.",
                    "last": "Jain"
                },
                {
                    "first": "Gustavo Adolfo Hernandez",
                    "initial": "G.A.H.",
                    "last": "Suarez"
                },
                {
                    "first": "Luis Estuardo",
                    "initial": "L.E.",
                    "last": "Lombardi"
                },
                {
                    "first": "Aekunbiola",
                    "initial": "A.",
                    "last": "Banjo"
                },
                {
                    "first": "Clara",
                    "initial": "C.",
                    "last": "Men\u00e9ndez"
                },
                {
                    "first": "Efr\u00e9n Javier",
                    "initial": "E.J.",
                    "last": "Domingo"
                },
                {
                    "first": "Julio",
                    "initial": "J.",
                    "last": "Velasco"
                },
                {
                    "first": "Ashrafun",
                    "initial": "A.",
                    "last": "Nessa"
                },
                {
                    "first": "Saibua C.Bunnag",
                    "initial": "S.C.B.",
                    "last": "Chichareon"
                },
                {
                    "first": "You Lin",
                    "initial": "Y.L.",
                    "last": "Qiao"
                },
                {
                    "first": "Enrique",
                    "initial": "E.",
                    "last": "Lerma"
                },
                {
                    "first": "Suzanne M.",
                    "initial": "S.M.",
                    "last": "Garland"
                },
                {
                    "first": "Toshiyuki",
                    "initial": "T.",
                    "last": "Sasagawa"
                },
                {
                    "first": "Annabelle",
                    "initial": "A.",
                    "last": "Ferrera"
                },
                {
                    "first": "Doudja",
                    "initial": "D.",
                    "last": "Hammouda"
                },
                {
                    "first": "Luciano",
                    "initial": "L.",
                    "last": "Mariani"
                },
                {
                    "first": "Adela",
                    "initial": "A.",
                    "last": "Pelayo"
                },
                {
                    "first": "Ivo",
                    "initial": "I.",
                    "last": "Steiner"
                },
                {
                    "first": "Esther",
                    "initial": "E.",
                    "last": "Oliva"
                },
                {
                    "first": "Chris J.L.M.",
                    "initial": "C.J.L.M.",
                    "last": "Meijer"
                },
                {
                    "first": "Waleed Fahad",
                    "initial": "W.F.",
                    "last": "Al-Jassar"
                },
                {
                    "first": "Eugenia",
                    "initial": "E.",
                    "last": "Cruz"
                },
                {
                    "first": "Thomas C.",
                    "initial": "T.C.",
                    "last": "Wright"
                },
                {
                    "first": "Ana",
                    "initial": "A.",
                    "last": "Puras"
                },
                {
                    "first": "Cecilia Ladines",
                    "initial": "C.L.",
                    "last": "Llave"
                },
                {
                    "first": "Maria",
                    "initial": "M.",
                    "last": "Tzardi"
                },
                {
                    "first": "Theodoros",
                    "initial": "T.",
                    "last": "Agorastos"
                },
                {
                    "first": "Victoria",
                    "initial": "V.",
                    "last": "Garcia-Barriola"
                },
                {
                    "first": "Christine",
                    "initial": "C.",
                    "last": "Clavel"
                },
                {
                    "first": "Jaume",
                    "initial": "J.",
                    "last": "Ordi"
                },
                {
                    "first": "Miguel",
                    "initial": "M.",
                    "last": "And\u00fajar"
                },
                {
                    "first": "Xavier",
                    "initial": "X.",
                    "last": "Castellsagu\u00e9"
                },
                {
                    "first": "Gloria I.",
                    "initial": "G.I.",
                    "last": "S\u00e1nchez"
                },
                {
                    "first": "Andrzej Marcin",
                    "initial": "A.M.",
                    "last": "Nowakowski"
                },
                {
                    "first": "Jacob",
                    "initial": "J.",
                    "last": "Bornstein"
                },
                {
                    "first": "Nubia",
                    "initial": "N.",
                    "last": "Mu\u00f1oz"
                },
                {
                    "first": "F. Xavier",
                    "initial": "F.X.",
                    "last": "Bosch"
                }
            ],
            "doi": "10.1016/S1470-2045(10)70230-8",
            "firstpage": "1048",
            "issn": "14702045",
            "lastpage": "1056",
            "pmid": "20952254",
            "pub_year": 2010,
            "title": "Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study",
            "volume": "11"
        },
        "b0015": {
            "authors": [
                {
                    "first": "Ni",
                    "initial": "N.",
                    "last": "Li"
                },
                {
                    "first": "Silvia",
                    "initial": "S.",
                    "last": "Franceschi"
                },
                {
                    "first": "Rebecca",
                    "initial": "R.",
                    "last": "Howell-Jones"
                },
                {
                    "first": "Peter J.F.",
                    "initial": "P.J.F.",
                    "last": "Snijders"
                },
                {
                    "first": "Gary M.",
                    "initial": "G.M.",
                    "last": "Clifford"
                }
            ],
            "doi": "10.1002/ijc.25396",
            "firstpage": "927",
            "issn": "00207136",
            "lastpage": "935",
            "pmid": "20473886",
            "pub_year": 2011,
            "title": "Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication",
            "volume": "128"
        },
        "b0020": null,
        "b0025": {
            "authors": [
                {
                    "first": "Court",
                    "initial": "C.",
                    "last": "Pedersen"
                },
                {
                    "first": "Tiina",
                    "initial": "T.",
                    "last": "Petaja"
                },
                {
                    "first": "Gitte",
                    "initial": "G.",
                    "last": "Strauss"
                },
                {
                    "first": "Hans C.",
                    "initial": "H.C.",
                    "last": "Rumke"
                },
                {
                    "first": "Airi",
                    "initial": "A.",
                    "last": "Poder"
                },
                {
                    "first": "Jan Hendrik",
                    "initial": "J.H.",
                    "last": "Richardus"
                },
                {
                    "first": "Bart",
                    "initial": "B.",
                    "last": "Spiessens"
                },
                {
                    "first": "Dominique",
                    "initial": "D.",
                    "last": "Descamps"
                },
                {
                    "first": "Karin",
                    "initial": "K.",
                    "last": "Hardt"
                },
                {
                    "first": "Matti",
                    "initial": "M.",
                    "last": "Lehtinen"
                },
                {
                    "first": "Gary",
                    "initial": "G.",
                    "last": "Dubin"
                }
            ],
            "doi": "10.1016/j.jadohealth.2007.02.015",
            "firstpage": "564",
            "issn": "1054139X",
            "lastpage": "571",
            "pmid": "17531764",
            "pub_year": 2007,
            "title": "Immunization of Early Adolescent Females with Human Papillomavirus Type 16 and 18 L1 Virus-Like Particle Vaccine Containing AS04 Adjuvant",
            "volume": "40"
        },
        "b0030": {
            "authors": [
                {
                    "first": "Stan L.",
                    "initial": "S.L.",
                    "last": "Block"
                },
                {
                    "first": "Terry",
                    "initial": "T.",
                    "last": "Nolan"
                },
                {
                    "first": "Carlos",
                    "initial": "C.",
                    "last": "Sattler"
                },
                {
                    "first": "Eliav",
                    "initial": "E.",
                    "last": "Barr"
                },
                {
                    "first": "Katherine E.D.",
                    "initial": "K.E.D.",
                    "last": "Giacoletti"
                },
                {
                    "first": "Colin D.",
                    "initial": "C.D.",
                    "last": "Marchant"
                },
                {
                    "first": "Xavier",
                    "initial": "X.",
                    "last": "Castellsagu\u00e9"
                },
                {
                    "first": "Steven A.",
                    "initial": "S.A.",
                    "last": "Rusche"
                },
                {
                    "first": "Suzanne",
                    "initial": "S.",
                    "last": "Lukac"
                },
                {
                    "first": "Janine T.",
                    "initial": "J.T.",
                    "last": "Bryan"
                },
                {
                    "first": "Paul F.",
                    "initial": "P.F.",
                    "last": "Cavanaugh"
                },
                {
                    "first": "Keith S.",
                    "initial": "K.S.",
                    "last": "Reisinger"
                }
            ],
            "doi": "10.1542/peds.2006-0461",
            "firstpage": "2135",
            "issn": "00314005",
            "lastpage": "2145",
            "pmid": "17079588",
            "pub_year": 2006,
            "title": "Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women",
            "volume": "118"
        },
        "b0035": {
            "authors": [
                {
                    "first": "Diane M.",
                    "initial": "D.M.",
                    "last": "Harper"
                },
                {
                    "first": "Eduardo L.",
                    "initial": "E.L.",
                    "last": "Franco"
                },
                {
                    "first": "Cosette",
                    "initial": "C.",
                    "last": "Wheeler"
                },
                {
                    "first": "Daron G.",
                    "initial": "D.G.",
                    "last": "Ferris"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Jenkins"
                },
                {
                    "first": "Anne",
                    "initial": "A.",
                    "last": "Schuind"
                },
                {
                    "first": "Toufik",
                    "initial": "T.",
                    "last": "Zahaf"
                },
                {
                    "first": "Bruce",
                    "initial": "B.",
                    "last": "Innis"
                },
                {
                    "first": "Paulo",
                    "initial": "P.",
                    "last": "Naud"
                },
                {
                    "first": "Newton S.",
                    "initial": "N.S.",
                    "last": "De Carvalho"
                },
                {
                    "first": "Cecilia M.",
                    "initial": "C.M.",
                    "last": "Roteli-Martins"
                },
                {
                    "first": "Julio",
                    "initial": "J.",
                    "last": "Teixeira"
                },
                {
                    "first": "Mark M.",
                    "initial": "M.M.",
                    "last": "Blatter"
                },
                {
                    "first": "Abner P.",
                    "initial": "A.P.",
                    "last": "Korn"
                },
                {
                    "first": "Wim",
                    "initial": "W.",
                    "last": "Quint"
                },
                {
                    "first": "Gary",
                    "initial": "G.",
                    "last": "Dubin"
                }
            ],
            "doi": "10.1016/S0140-6736(04)17398-4",
            "firstpage": "1757",
            "issn": "01406736",
            "lastpage": "1765",
            "pmid": "15541448",
            "pub_year": 2004,
            "title": "Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomised controlled trial",
            "volume": "364"
        },
        "b0040": {
            "authors": [
                {
                    "first": "Diane M.",
                    "initial": "D.M.",
                    "last": "Harper"
                },
                {
                    "first": "Eduardo L.",
                    "initial": "E.L.",
                    "last": "Franco"
                },
                {
                    "first": "Cosette M.",
                    "initial": "C.M.",
                    "last": "Wheeler"
                },
                {
                    "first": "Anna Barbara",
                    "initial": "A.B.",
                    "last": "Moscicki"
                },
                {
                    "first": "Barbara",
                    "initial": "B.",
                    "last": "Romanowski"
                },
                {
                    "first": "Cecilia M.",
                    "initial": "C.M.",
                    "last": "Roteli-Martins"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Jenkins"
                },
                {
                    "first": "Anne",
                    "initial": "A.",
                    "last": "Schuind"
                },
                {
                    "first": "Sue Ann",
                    "initial": "S.A.",
                    "last": "Costa Clemens"
                },
                {
                    "first": "Gary",
                    "initial": "G.",
                    "last": "Dubin"
                }
            ],
            "doi": "10.1016/S0140-6736(06)68439-0",
            "firstpage": "1247",
            "issn": "01406736",
            "lastpage": "1255",
            "pmid": "16631880",
            "pub_year": 2006,
            "title": "Sustained efficacy up to 4\u00b75 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial",
            "volume": "367"
        },
        "b0045": {
            "authors": [
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Paavonen"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Naud"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Salmer\u00f3n"
                },
                {
                    "first": "CM M.",
                    "initial": "C.M.",
                    "last": "Wheeler"
                },
                {
                    "first": "S. N.",
                    "initial": "S.N.",
                    "last": "Chow"
                },
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "Apter"
                },
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Kitchener"
                },
                {
                    "first": "X.",
                    "initial": "X.",
                    "last": "Castellsague"
                },
                {
                    "first": "JC C.",
                    "initial": "J.C.",
                    "last": "Teixeira"
                },
                {
                    "first": "SR R.",
                    "initial": "S.R.",
                    "last": "Skinner"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Hedrick"
                },
                {
                    "first": "U.",
                    "initial": "U.",
                    "last": "Jaisamrarn"
                },
                {
                    "first": "G.",
                    "initial": "G.",
                    "last": "Limson"
                },
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "Garland"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Szarewski"
                },
                {
                    "first": "B.",
                    "initial": "B.",
                    "last": "Romanowski"
                },
                {
                    "first": "FY Y.",
                    "initial": "F.Y.",
                    "last": "Aoki"
                },
                {
                    "first": "TF F.",
                    "initial": "T.F.",
                    "last": "Schwarz"
                },
                {
                    "first": "WAJ",
                    "initial": "W.",
                    "last": "Poppe"
                },
                {
                    "first": "FX X.",
                    "initial": "F.X.",
                    "last": "Bosch"
                },
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "Jenkins"
                },
                {
                    "first": "K.",
                    "initial": "K.",
                    "last": "Hardt"
                },
                {
                    "first": "T.",
                    "initial": "T.",
                    "last": "Zahaf"
                },
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "Descamps"
                },
                {
                    "first": "F.",
                    "initial": "F.",
                    "last": "Struyf"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Lehtinen"
                },
                {
                    "first": "G.",
                    "initial": "G.",
                    "last": "Dubin"
                }
            ],
            "doi": "10.1016/S0140-6736(09)61248-4",
            "firstpage": "301",
            "issn": "01406736",
            "lastpage": "314",
            "pmid": "19586656",
            "pub_year": 2009,
            "title": "Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women",
            "volume": "374"
        },
        "b0050": {
            "authors": [
                {
                    "first": "Matti",
                    "initial": "M.",
                    "last": "Lehtinen"
                },
                {
                    "first": "Jorma",
                    "initial": "J.",
                    "last": "Paavonen"
                },
                {
                    "first": "Cosette M.",
                    "initial": "C.M.",
                    "last": "Wheeler"
                },
                {
                    "first": "Unnop",
                    "initial": "U.",
                    "last": "Jaisamrarn"
                },
                {
                    "first": "Suzanne M.",
                    "initial": "S.M.",
                    "last": "Garland"
                },
                {
                    "first": "Xavier",
                    "initial": "X.",
                    "last": "Castellsagu\u00e9"
                },
                {
                    "first": "S. Rachel",
                    "initial": "S.R.",
                    "last": "Skinner"
                },
                {
                    "first": "Dan",
                    "initial": "D.",
                    "last": "Apter"
                },
                {
                    "first": "Paulo",
                    "initial": "P.",
                    "last": "Naud"
                },
                {
                    "first": "Jorge",
                    "initial": "J.",
                    "last": "Salmer\u00f3n"
                },
                {
                    "first": "Song Nan",
                    "initial": "S.N.",
                    "last": "Chow"
                },
                {
                    "first": "Henry",
                    "initial": "H.",
                    "last": "Kitchener"
                },
                {
                    "first": "J\u00falio C.",
                    "initial": "J.C.",
                    "last": "Teixeira"
                },
                {
                    "first": "James",
                    "initial": "J.",
                    "last": "Hedrick"
                },
                {
                    "first": "Genara",
                    "initial": "G.",
                    "last": "Limson"
                },
                {
                    "first": "Anne",
                    "initial": "A.",
                    "last": "Szarewski"
                },
                {
                    "first": "Barbara",
                    "initial": "B.",
                    "last": "Romanowski"
                },
                {
                    "first": "Fred Y.",
                    "initial": "F.Y.",
                    "last": "Aoki"
                },
                {
                    "first": "Tino F.",
                    "initial": "T.F.",
                    "last": "Schwarz"
                },
                {
                    "first": "Willy A.J.",
                    "initial": "W.A.J.",
                    "last": "Poppe"
                },
                {
                    "first": "Newton S.",
                    "initial": "N.S.",
                    "last": "De Carvalho"
                },
                {
                    "first": "Maria Julieta V.",
                    "initial": "M.J.V.",
                    "last": "Germar"
                },
                {
                    "first": "Klaus",
                    "initial": "K.",
                    "last": "Peters"
                },
                {
                    "first": "Adrian",
                    "initial": "A.",
                    "last": "Mindel"
                },
                {
                    "first": "Philippe",
                    "initial": "P.",
                    "last": "De Sutter"
                },
                {
                    "first": "F. Xavier",
                    "initial": "F.X.",
                    "last": "Bosch"
                },
                {
                    "first": "Marie Pierre",
                    "initial": "M.P.",
                    "last": "David"
                },
                {
                    "first": "Dominique",
                    "initial": "D.",
                    "last": "Descamps"
                },
                {
                    "first": "Frank",
                    "initial": "F.",
                    "last": "Struyf"
                },
                {
                    "first": "Gary",
                    "initial": "G.",
                    "last": "Dubin"
                }
            ],
            "doi": "10.1016/S1470-2045(11)70286-8",
            "firstpage": "89",
            "issn": "14702045",
            "lastpage": "99",
            "pmid": "22075171",
            "pub_year": 2012,
            "title": "Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial",
            "volume": "13"
        },
        "b0055": {
            "authors": [
                {
                    "first": "Cosette M.",
                    "initial": "C.M.",
                    "last": "Wheeler"
                },
                {
                    "first": "Xavier",
                    "initial": "X.",
                    "last": "Castellsagu\u00e9"
                },
                {
                    "first": "Suzanne M.",
                    "initial": "S.M.",
                    "last": "Garland"
                },
                {
                    "first": "Anne",
                    "initial": "A.",
                    "last": "Szarewski"
                },
                {
                    "first": "Jorma",
                    "initial": "J.",
                    "last": "Paavonen"
                },
                {
                    "first": "Paulo",
                    "initial": "P.",
                    "last": "Naud"
                },
                {
                    "first": "Jorge",
                    "initial": "J.",
                    "last": "Salmer\u00f3n"
                },
                {
                    "first": "Song Nan",
                    "initial": "S.N.",
                    "last": "Chow"
                },
                {
                    "first": "Dan",
                    "initial": "D.",
                    "last": "Apter"
                },
                {
                    "first": "Henry",
                    "initial": "H.",
                    "last": "Kitchener"
                },
                {
                    "first": "J\u00falio C.",
                    "initial": "J.C.",
                    "last": "Teixeira"
                },
                {
                    "first": "S. Rachel",
                    "initial": "S.R.",
                    "last": "Skinner"
                },
                {
                    "first": "Unnop",
                    "initial": "U.",
                    "last": "Jaisamrarn"
                },
                {
                    "first": "Genara",
                    "initial": "G.",
                    "last": "Limson"
                },
                {
                    "first": "Barbara",
                    "initial": "B.",
                    "last": "Romanowski"
                },
                {
                    "first": "Fred Y.",
                    "initial": "F.Y.",
                    "last": "Aoki"
                },
                {
                    "first": "Tino F.",
                    "initial": "T.F.",
                    "last": "Schwarz"
                },
                {
                    "first": "Willy A.J.",
                    "initial": "W.A.J.",
                    "last": "Poppe"
                },
                {
                    "first": "F. Xavier",
                    "initial": "F.X.",
                    "last": "Bosch"
                },
                {
                    "first": "Diane M.",
                    "initial": "D.M.",
                    "last": "Harper"
                },
                {
                    "first": "Warner",
                    "initial": "W.",
                    "last": "Huh"
                },
                {
                    "first": "Karin",
                    "initial": "K.",
                    "last": "Hardt"
                },
                {
                    "first": "Toufik",
                    "initial": "T.",
                    "last": "Zahaf"
                },
                {
                    "first": "Dominique",
                    "initial": "D.",
                    "last": "Descamps"
                },
                {
                    "first": "Frank",
                    "initial": "F.",
                    "last": "Struyf"
                },
                {
                    "first": "Gary",
                    "initial": "G.",
                    "last": "Dubin"
                },
                {
                    "first": "Matti",
                    "initial": "M.",
                    "last": "Lehtinen"
                }
            ],
            "doi": "10.1016/S1470-2045(11)70287-X",
            "firstpage": "100",
            "issn": "14702045",
            "lastpage": "110",
            "pmid": "22075170",
            "pub_year": 2012,
            "title": "Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial",
            "volume": "13"
        },
        "b0060": {
            "authors": [
                {
                    "first": "Luisa L.",
                    "initial": "L.L.",
                    "last": "Villa"
                },
                {
                    "first": "Gonzalo",
                    "initial": "G.",
                    "last": "Perez"
                },
                {
                    "first": "Susanne Kr\u00fcger",
                    "initial": "S.K.",
                    "last": "Kj\u00e6r"
                },
                {
                    "first": "Jorma",
                    "initial": "J.",
                    "last": "Paavonen"
                },
                {
                    "first": "Matti",
                    "initial": "M.",
                    "last": "Lehtinen"
                },
                {
                    "first": "Nubia",
                    "initial": "N.",
                    "last": "Mu\u00f1oz"
                },
                {
                    "first": "Kristj\u00e1n",
                    "initial": "K.",
                    "last": "Sigurdsson"
                },
                {
                    "first": "Mauricio",
                    "initial": "M.",
                    "last": "Hernandez-Avila"
                },
                {
                    "first": "Ole Eric",
                    "initial": "O.E.",
                    "last": "Iversen"
                },
                {
                    "first": "Steinar",
                    "initial": "S.",
                    "last": "Thoresen"
                },
                {
                    "first": "Patricia J.",
                    "initial": "P.J.",
                    "last": "Garc\u00eda"
                },
                {
                    "first": "Slawomir",
                    "initial": "S.",
                    "last": "Majewski"
                },
                {
                    "first": "Hseon Tay",
                    "initial": "H.T.",
                    "last": "Eng"
                },
                {
                    "first": "F. Xavier",
                    "initial": "F.X.",
                    "last": "Bosch"
                },
                {
                    "first": "Joakim",
                    "initial": "J.",
                    "last": "Dillner"
                },
                {
                    "first": "Sven Eric",
                    "initial": "S.E.",
                    "last": "Olsson"
                },
                {
                    "first": "Kevin A.",
                    "initial": "K.A.",
                    "last": "Ault"
                },
                {
                    "first": "Darron R.",
                    "initial": "D.R.",
                    "last": "Brown"
                },
                {
                    "first": "Daron G.",
                    "initial": "D.G.",
                    "last": "Ferris"
                },
                {
                    "first": "Laura A.",
                    "initial": "L.A.",
                    "last": "Koutsky"
                },
                {
                    "first": "Robert J.",
                    "initial": "R.J.",
                    "last": "Kurman"
                },
                {
                    "first": "Evan R.",
                    "initial": "E.R.",
                    "last": "Myers"
                },
                {
                    "first": "Eliav",
                    "initial": "E.",
                    "last": "Barr"
                },
                {
                    "first": "John",
                    "initial": "J.",
                    "last": "Boslego"
                },
                {
                    "first": "Janine",
                    "initial": "J.",
                    "last": "Bryan"
                },
                {
                    "first": "Mark T.",
                    "initial": "M.T.",
                    "last": "Esser"
                },
                {
                    "first": "Teresa M.",
                    "initial": "T.M.",
                    "last": "Hesley"
                },
                {
                    "first": "Micki",
                    "initial": "M.",
                    "last": "Nelson"
                },
                {
                    "first": "Radha",
                    "initial": "R.",
                    "last": "Railkar"
                },
                {
                    "first": "Margaret",
                    "initial": "M.",
                    "last": "James"
                },
                {
                    "first": "Carlos",
                    "initial": "C.",
                    "last": "Sattler"
                },
                {
                    "first": "Frank J.",
                    "initial": "F.J.",
                    "last": "Taddeo"
                },
                {
                    "first": "Annemarie R.",
                    "initial": "A.R.",
                    "last": "Thornton"
                },
                {
                    "first": "Scott C.",
                    "initial": "S.C.",
                    "last": "Vuocolo"
                }
            ],
            "doi": "10.1086/522864",
            "firstpage": "1438",
            "issn": "00221899",
            "lastpage": "1446",
            "pmid": "18008221",
            "pub_year": 2007,
            "title": "Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV Infection",
            "volume": "196"
        },
        "b0065": {
            "authors": [
                {
                    "first": "Kevin A.",
                    "initial": "K.A.",
                    "last": "Ault"
                }
            ],
            "doi": "10.1016/S0140-6736(07)60852-6",
            "firstpage": "1861",
            "issn": "01406736",
            "lastpage": "1868",
            "pmid": "17544766",
            "pub_year": 2007,
            "title": "Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials",
            "volume": "369"
        },
        "b0070": null,
        "b0075": null,
        "b0080": null,
        "b0085": {
            "authors": [
                {
                    "first": "Mark H.",
                    "initial": "M.H.",
                    "last": "Einstein"
                },
                {
                    "first": "Mira",
                    "initial": "M.",
                    "last": "Baron"
                },
                {
                    "first": "Myron J.",
                    "initial": "M.J.",
                    "last": "Levin"
                },
                {
                    "first": "Archana",
                    "initial": "A.",
                    "last": "Chatterjee"
                },
                {
                    "first": "Bradley",
                    "initial": "B.",
                    "last": "Fox"
                },
                {
                    "first": "Sofia",
                    "initial": "S.",
                    "last": "Scholar"
                },
                {
                    "first": "Jeffrey",
                    "initial": "J.",
                    "last": "Rosen"
                },
                {
                    "first": "Nahida",
                    "initial": "N.",
                    "last": "Chakhtoura"
                },
                {
                    "first": "Doroth\u00e9e",
                    "initial": "D.",
                    "last": "Meric"
                },
                {
                    "first": "Francis J.",
                    "initial": "F.J.",
                    "last": "Dessy"
                },
                {
                    "first": "Sanjoy K.",
                    "initial": "S.K.",
                    "last": "Datta"
                },
                {
                    "first": "Dominique",
                    "initial": "D.",
                    "last": "Descamps"
                },
                {
                    "first": "Gary",
                    "initial": "G.",
                    "last": "Dubin"
                }
            ],
            "doi": "10.4161/hv.7.12.18281",
            "firstpage": "1343",
            "issn": "15548600",
            "lastpage": "1358",
            "pmid": "22048173",
            "pub_year": 2011,
            "title": "Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: Follow-up from months 12-24 in a phase III randomized study of healthy women aged 18-45 y",
            "volume": "7"
        },
        "b0090": {
            "authors": [
                {
                    "first": "Mark H.",
                    "initial": "M.H.",
                    "last": "Einstein"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Takacs"
                },
                {
                    "first": "Archana",
                    "initial": "A.",
                    "last": "Chatterjee"
                },
                {
                    "first": "Rhoda S.",
                    "initial": "R.S.",
                    "last": "Sperling"
                },
                {
                    "first": "Nahida",
                    "initial": "N.",
                    "last": "Chakhtoura"
                },
                {
                    "first": "Mark M.",
                    "initial": "M.M.",
                    "last": "Blatter"
                },
                {
                    "first": "Jacob",
                    "initial": "J.",
                    "last": "Lalezari"
                },
                {
                    "first": "Marie Pierre",
                    "initial": "M.P.",
                    "last": "David"
                },
                {
                    "first": "Lan",
                    "initial": "L.",
                    "last": "Lin"
                },
                {
                    "first": "Frank",
                    "initial": "F.",
                    "last": "Struyf"
                },
                {
                    "first": "Gary",
                    "initial": "G.",
                    "last": "Dubin"
                },
                {
                    "first": null,
                    "initial": null,
                    "last": null
                }
            ],
            "doi": "10.4161/hv.36121",
            "firstpage": "3435",
            "issn": "21645515",
            "lastpage": "3445",
            "pmid": "25483701",
            "pub_year": 2014,
            "title": "Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: End-of-study analysis of a Phase III randomized trial",
            "volume": "10"
        },
        "b0095": {
            "authors": [
                {
                    "first": "Mark H.",
                    "initial": "M.H.",
                    "last": "Einstein"
                },
                {
                    "first": "Myron J.",
                    "initial": "M.J.",
                    "last": "Levin"
                },
                {
                    "first": "Archana",
                    "initial": "A.",
                    "last": "Chatterjee"
                },
                {
                    "first": "Nahida",
                    "initial": "N.",
                    "last": "Chakhtoura"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Takacs"
                },
                {
                    "first": "Gr\u00e9gory",
                    "initial": "G.",
                    "last": "Catteau"
                },
                {
                    "first": "Francis J.",
                    "initial": "F.J.",
                    "last": "Dessy"
                },
                {
                    "first": "Philippe",
                    "initial": "P.",
                    "last": "Moris"
                },
                {
                    "first": "Lan",
                    "initial": "L.",
                    "last": "Lin"
                },
                {
                    "first": "Frank",
                    "initial": "F.",
                    "last": "Struyf"
                },
                {
                    "first": "Gary",
                    "initial": "G.",
                    "last": "Dubin"
                },
                {
                    "first": "Mark",
                    "initial": "M.",
                    "last": "Blatter"
                },
                {
                    "first": "Christopher V.",
                    "initial": "C.V.",
                    "last": "Chambers"
                },
                {
                    "first": "Marina",
                    "initial": "M.",
                    "last": "Fernandez"
                },
                {
                    "first": "Bradley",
                    "initial": "B.",
                    "last": "Fox"
                },
                {
                    "first": "David L.",
                    "initial": "D.L.",
                    "last": "Fried"
                },
                {
                    "first": "Sidney A.",
                    "initial": "S.A.",
                    "last": "Funk"
                },
                {
                    "first": "Cheryl A.",
                    "initial": "C.A.",
                    "last": "Hansen"
                },
                {
                    "first": "James A.",
                    "initial": "J.A.",
                    "last": "Hedrick"
                },
                {
                    "first": "Bethany",
                    "initial": "B.",
                    "last": "Hoffman"
                },
                {
                    "first": "Terry D.",
                    "initial": "T.D.",
                    "last": "Klein"
                },
                {
                    "first": "Jacob",
                    "initial": "J.",
                    "last": "Lalezari"
                },
                {
                    "first": "Michael J.",
                    "initial": "M.J.",
                    "last": "Noss"
                },
                {
                    "first": "James H.",
                    "initial": "J.H.",
                    "last": "Silverblatt"
                },
                {
                    "first": "Rhoda S.",
                    "initial": "R.S.",
                    "last": "Sperling"
                },
                {
                    "first": "Karen G.",
                    "initial": "K.G.",
                    "last": "Swenson"
                },
                {
                    "first": "Troy",
                    "initial": "T.",
                    "last": "Thompson"
                },
                {
                    "first": "Mark",
                    "initial": "M.",
                    "last": "Turner"
                },
                {
                    "first": "Michael W.",
                    "initial": "M.W.",
                    "last": "Warren"
                },
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "Yoachim"
                }
            ],
            "doi": "10.4161/hv.36117",
            "firstpage": "3455",
            "issn": "21645515",
            "lastpage": "3465",
            "pmid": "25483700",
            "pub_year": 2014,
            "title": "Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: Follow-up through Month 48 in a Phase III randomized study",
            "volume": "10"
        },
        "b0100": {
            "authors": [
                {
                    "first": "Mark H.",
                    "initial": "M.H.",
                    "last": "Einstein"
                },
                {
                    "first": "Mira",
                    "initial": "M.",
                    "last": "Baron"
                },
                {
                    "first": "Myron J.",
                    "initial": "M.J.",
                    "last": "Levin"
                },
                {
                    "first": "Archana",
                    "initial": "A.",
                    "last": "Chatterjee"
                },
                {
                    "first": "Robert P.",
                    "initial": "R.P.",
                    "last": "Edwards"
                },
                {
                    "first": "Fred",
                    "initial": "F.",
                    "last": "Zepp"
                },
                {
                    "first": "Isabelle",
                    "initial": "I.",
                    "last": "Carletti"
                },
                {
                    "first": "Francis J.",
                    "initial": "F.J.",
                    "last": "Dessy"
                },
                {
                    "first": "Andrew F.",
                    "initial": "A.F.",
                    "last": "Trofa"
                },
                {
                    "first": "Anne",
                    "initial": "A.",
                    "last": "Schuind"
                },
                {
                    "first": "Gary",
                    "initial": "G.",
                    "last": "Dubin"
                }
            ],
            "doi": "10.4161/hv.5.10.9518",
            "firstpage": "705",
            "issn": "15548600",
            "lastpage": "719",
            "pmid": "19684472",
            "pub_year": 2009,
            "title": "Comparison of the immunogenicity and safety of Cervarix\u2122 and Gardasil\u00ae human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years",
            "volume": "5"
        },
        "b0105": {
            "authors": [
                {
                    "first": "Mark H.",
                    "initial": "M.H.",
                    "last": "Einstein"
                },
                {
                    "first": "Mira",
                    "initial": "M.",
                    "last": "Baron"
                },
                {
                    "first": "Myron J.",
                    "initial": "M.J.",
                    "last": "Levin"
                },
                {
                    "first": "Archana",
                    "initial": "A.",
                    "last": "Chatterjee"
                },
                {
                    "first": "Bradley",
                    "initial": "B.",
                    "last": "Fox"
                },
                {
                    "first": "Sofia",
                    "initial": "S.",
                    "last": "Scholar"
                },
                {
                    "first": "Jeffrey",
                    "initial": "J.",
                    "last": "Rosen"
                },
                {
                    "first": "Nahida",
                    "initial": "N.",
                    "last": "Chakhtoura"
                },
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Lebacq"
                },
                {
                    "first": "Robbert",
                    "initial": "R.",
                    "last": "Van Der Most"
                },
                {
                    "first": "Philippe",
                    "initial": "P.",
                    "last": "Moris"
                },
                {
                    "first": "Sandra L.",
                    "initial": "S.L.",
                    "last": "Giannini"
                },
                {
                    "first": "Anne",
                    "initial": "A.",
                    "last": "Schuind"
                },
                {
                    "first": "Sanjoy K.",
                    "initial": "S.K.",
                    "last": "Datta"
                },
                {
                    "first": "Dominique",
                    "initial": "D.",
                    "last": "Descamps"
                }
            ],
            "doi": "10.4161/hv.7.12.18282",
            "firstpage": "1359",
            "issn": "15548600",
            "lastpage": "1373",
            "pmid": "22048172",
            "pub_year": 2011,
            "title": "Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years",
            "volume": "7"
        },
        "b0110": {
            "authors": [
                {
                    "first": "Francis J.",
                    "initial": "F.J.",
                    "last": "Dessy"
                },
                {
                    "first": "Sandra L.",
                    "initial": "S.L.",
                    "last": "Giannini"
                },
                {
                    "first": "Catherine A.",
                    "initial": "C.A.",
                    "last": "Bougelet"
                },
                {
                    "first": "Troy J.",
                    "initial": "T.J.",
                    "last": "Kemp"
                },
                {
                    "first": "Marie Pierre M.",
                    "initial": "M.P.M.",
                    "last": "David"
                },
                {
                    "first": "Sylviane M.",
                    "initial": "S.M.",
                    "last": "Poncelet"
                },
                {
                    "first": "Ligia A.",
                    "initial": "L.A.",
                    "last": "Pinto"
                },
                {
                    "first": "Martine A.",
                    "initial": "M.A.",
                    "last": "Wettendorff"
                }
            ],
            "doi": "10.4161/hv.4.6.6912",
            "firstpage": "425",
            "issn": "15548600",
            "lastpage": "434",
            "pmid": "18948732",
            "pub_year": 2008,
            "title": "Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine",
            "volume": "4"
        },
        "b0115": {
            "authors": [
                {
                    "first": "Diana V.",
                    "initial": "D.V.",
                    "last": "Pastrana"
                },
                {
                    "first": "Christopher B.",
                    "initial": "C.B.",
                    "last": "Buck"
                },
                {
                    "first": "Yuk Ying S.",
                    "initial": "Y.Y.S.",
                    "last": "Pang"
                },
                {
                    "first": "Cynthia D.",
                    "initial": "C.D.",
                    "last": "Thompson"
                },
                {
                    "first": "Philip E.",
                    "initial": "P.E.",
                    "last": "Castle"
                },
                {
                    "first": "Peter C.",
                    "initial": "P.C.",
                    "last": "FitzGerald"
                },
                {
                    "first": "Susanne Kr\u00fcger",
                    "initial": "S.K.",
                    "last": "Kjaer"
                },
                {
                    "first": "Douglas R.",
                    "initial": "D.R.",
                    "last": "Lowy"
                },
                {
                    "first": "John T.",
                    "initial": "J.T.",
                    "last": "Schiller"
                }
            ],
            "doi": "10.1016/j.virol.2003.12.027",
            "firstpage": "205",
            "issn": "00426822",
            "lastpage": "216",
            "pmid": "15051381",
            "pub_year": 2004,
            "title": "Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18",
            "volume": "321"
        },
        "b0120": {
            "authors": [
                {
                    "first": "Shane",
                    "initial": "S.",
                    "last": "Crotty"
                },
                {
                    "first": "Rachael D.",
                    "initial": "R.D.",
                    "last": "Aubert"
                },
                {
                    "first": "John",
                    "initial": "J.",
                    "last": "Glidewell"
                },
                {
                    "first": "Rafi",
                    "initial": "R.",
                    "last": "Ahmed"
                }
            ],
            "doi": "10.1016/j.jim.2003.12.015",
            "firstpage": "111",
            "issn": "00221759",
            "lastpage": "122",
            "pmid": "15087226",
            "pub_year": 2004,
            "title": "Tracking human antigen-specific memory B cells: A sensitive and generalized ELISPOT system",
            "volume": "286"
        },
        "b0125": {
            "authors": [
                {
                    "first": "Sandra L.",
                    "initial": "S.L.",
                    "last": "Giannini"
                },
                {
                    "first": "Emmanuel",
                    "initial": "E.",
                    "last": "Hanon"
                },
                {
                    "first": "Philippe",
                    "initial": "P.",
                    "last": "Moris"
                },
                {
                    "first": "Marcelle",
                    "initial": "M.",
                    "last": "Van Mechelen"
                },
                {
                    "first": "Sandra",
                    "initial": "S.",
                    "last": "Morel"
                },
                {
                    "first": "Francis",
                    "initial": "F.",
                    "last": "Dessy"
                },
                {
                    "first": "Marc A.",
                    "initial": "M.A.",
                    "last": "Fourneau"
                },
                {
                    "first": "Brigitte",
                    "initial": "B.",
                    "last": "Colau"
                },
                {
                    "first": "Joann",
                    "initial": "J.",
                    "last": "Suzich"
                },
                {
                    "first": "Genevieve",
                    "initial": "G.",
                    "last": "Losonksy"
                },
                {
                    "first": "Marie Th\u00e9r\u00e8se",
                    "initial": "M.T.",
                    "last": "Martin"
                },
                {
                    "first": "Gary",
                    "initial": "G.",
                    "last": "Dubin"
                },
                {
                    "first": "Martine A.",
                    "initial": "M.A.",
                    "last": "Wettendorff"
                }
            ],
            "doi": "10.1016/j.vaccine.2006.06.005",
            "firstpage": "5937",
            "issn": "0264410X",
            "lastpage": "5949",
            "pmid": "16828940",
            "pub_year": 2006,
            "title": "Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only",
            "volume": "24"
        },
        "b0130": {
            "authors": [
                {
                    "first": "Philippe",
                    "initial": "P.",
                    "last": "Moris"
                },
                {
                    "first": "Robbert",
                    "initial": "R.",
                    "last": "Van Der Most"
                },
                {
                    "first": "Isabel",
                    "initial": "I.",
                    "last": "Leroux-Roels"
                },
                {
                    "first": "Fr\u00e9d\u00e9ric",
                    "initial": "F.",
                    "last": "Clement"
                },
                {
                    "first": "Mamadou",
                    "initial": "M.",
                    "last": "Dram\u00e9"
                },
                {
                    "first": "Emmanuel",
                    "initial": "E.",
                    "last": "Hanon"
                },
                {
                    "first": "Geert G.",
                    "initial": "G.G.",
                    "last": "Leroux-Roels"
                },
                {
                    "first": "Marcelle",
                    "initial": "M.",
                    "last": "Van Mechelen"
                }
            ],
            "doi": "10.1007/s10875-010-9490-6",
            "firstpage": "443",
            "issn": "02719142",
            "lastpage": "454",
            "pmid": "21174144",
            "pub_year": 2011,
            "title": "H5N1 influenza vaccine formulated with AS03 A induces strong Cross-reactive and polyfunctional CD4 T-Cell responses",
            "volume": "31"
        },
        "b0135": {
            "authors": [
                {
                    "first": "Pratip K.",
                    "initial": "P.K.",
                    "last": "Chattopadhyay"
                },
                {
                    "first": "Joanne",
                    "initial": "J.",
                    "last": "Yu"
                },
                {
                    "first": "Mario",
                    "initial": "M.",
                    "last": "Roederer"
                }
            ],
            "doi": "10.1038/nprot.2006.1",
            "firstpage": "1",
            "issn": "17542189",
            "lastpage": "6",
            "pmid": "17406204",
            "pub_year": 2006,
            "title": "Live-cell assay to detect antigen-specific CD4+ T-cell responses by CD154 expression",
            "volume": "1"
        },
        "b0140": {
            "authors": [
                {
                    "first": "Marco",
                    "initial": "M.",
                    "last": "Frentsch"
                },
                {
                    "first": "Olga",
                    "initial": "O.",
                    "last": "Arbach"
                },
                {
                    "first": "Dennis",
                    "initial": "D.",
                    "last": "Kirchhoff"
                },
                {
                    "first": "Beate",
                    "initial": "B.",
                    "last": "Moewes"
                },
                {
                    "first": "Margitta",
                    "initial": "M.",
                    "last": "Worm"
                },
                {
                    "first": "Martin",
                    "initial": "M.",
                    "last": "Rothe"
                },
                {
                    "first": "Alexander",
                    "initial": "A.",
                    "last": "Scheffold"
                },
                {
                    "first": "Andreas",
                    "initial": "A.",
                    "last": "Thiel"
                }
            ],
            "doi": "10.1038/nm1292",
            "firstpage": "1118",
            "issn": "10788956",
            "lastpage": "1124",
            "pmid": "16186818",
            "pub_year": 2005,
            "title": "Direct access to CD4+ T cells specific for defined antigens according to CD154 expression",
            "volume": "11"
        },
        "b0145": {
            "authors": [
                {
                    "first": "Ting Fan",
                    "initial": "T.F.",
                    "last": "Leung"
                },
                {
                    "first": "Anthony Pak Yin",
                    "initial": "A.P.Y.",
                    "last": "Liu"
                },
                {
                    "first": "Fong Seng",
                    "initial": "F.S.",
                    "last": "Lim"
                },
                {
                    "first": "Franck",
                    "initial": "F.",
                    "last": "Thollot"
                },
                {
                    "first": "Helen May Lin",
                    "initial": "H.M.L.",
                    "last": "Oh"
                },
                {
                    "first": "Bee Wah",
                    "initial": "B.W.",
                    "last": "Lee"
                },
                {
                    "first": "Lars",
                    "initial": "L.",
                    "last": "Rombo"
                },
                {
                    "first": "Ngiap Chuan",
                    "initial": "N.C.",
                    "last": "Tan"
                },
                {
                    "first": "Roman",
                    "initial": "R.",
                    "last": "Rouzier"
                },
                {
                    "first": "Damien",
                    "initial": "D.",
                    "last": "Friel"
                },
                {
                    "first": "Benoit",
                    "initial": "B.",
                    "last": "de Muynck"
                },
                {
                    "first": "St\u00e9phanie",
                    "initial": "S.",
                    "last": "de Simoni"
                },
                {
                    "first": "Pemmaraju",
                    "initial": "P.",
                    "last": "Suryakiran"
                },
                {
                    "first": "Marjan",
                    "initial": "M.",
                    "last": "Hezareh"
                },
                {
                    "first": "Nicolas",
                    "initial": "N.",
                    "last": "Folschweiller"
                },
                {
                    "first": "Florence",
                    "initial": "F.",
                    "last": "Thomas"
                },
                {
                    "first": "Frank",
                    "initial": "F.",
                    "last": "Struyf"
                }
            ],
            "doi": "10.1080/21645515.2015.1050570",
            "firstpage": "1689",
            "issn": "21645515",
            "lastpage": "1702",
            "pmid": "26062002",
            "pub_year": 2015,
            "title": "Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9\u201314 years: Results to month 12 from a randomized trial",
            "volume": "11"
        },
        "b0150": null,
        "b0155": {
            "authors": [
                {
                    "first": "Jorma",
                    "initial": "J.",
                    "last": "Paavonen"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Jenkins"
                },
                {
                    "first": "F. Xavier",
                    "initial": "F.X.",
                    "last": "Bosch"
                },
                {
                    "first": "Paulo",
                    "initial": "P.",
                    "last": "Naud"
                },
                {
                    "first": "Jorge",
                    "initial": "J.",
                    "last": "Salmer\u00f3n"
                },
                {
                    "first": "Cosette M.",
                    "initial": "C.M.",
                    "last": "Wheeler"
                },
                {
                    "first": "Song Nan",
                    "initial": "S.N.",
                    "last": "Chow"
                },
                {
                    "first": "Dan L.",
                    "initial": "D.L.",
                    "last": "Apter"
                },
                {
                    "first": "Henry C.",
                    "initial": "H.C.",
                    "last": "Kitchener"
                },
                {
                    "first": "Xavier",
                    "initial": "X.",
                    "last": "Castellsague"
                },
                {
                    "first": "Newton S.",
                    "initial": "N.S.",
                    "last": "de Carvalho"
                },
                {
                    "first": "S. Rachel",
                    "initial": "S.R.",
                    "last": "Skinner"
                },
                {
                    "first": "Diane M.",
                    "initial": "D.M.",
                    "last": "Harper"
                },
                {
                    "first": "James A.",
                    "initial": "J.A.",
                    "last": "Hedrick"
                },
                {
                    "first": "Unnop",
                    "initial": "U.",
                    "last": "Jaisamrarn"
                },
                {
                    "first": "Genara AM",
                    "initial": "G.A.",
                    "last": "Limson"
                },
                {
                    "first": "Marc",
                    "initial": "M.",
                    "last": "Dionne"
                },
                {
                    "first": "Wim",
                    "initial": "W.",
                    "last": "Quint"
                },
                {
                    "first": "Bart",
                    "initial": "B.",
                    "last": "Spiessens"
                },
                {
                    "first": "Pascal",
                    "initial": "P.",
                    "last": "Peeters"
                },
                {
                    "first": "Frank",
                    "initial": "F.",
                    "last": "Struyf"
                },
                {
                    "first": "Susan L.",
                    "initial": "S.L.",
                    "last": "Wieting"
                },
                {
                    "first": "Matti O.",
                    "initial": "M.O.",
                    "last": "Lehtinen"
                },
                {
                    "first": "Gary",
                    "initial": "G.",
                    "last": "Dubin"
                }
            ],
            "doi": "10.1016/S0140-6736(07)60946-5",
            "firstpage": "2161",
            "issn": "01406736",
            "lastpage": "2170",
            "pmid": "17602732",
            "pub_year": 2007,
            "title": "Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial",
            "volume": "369"
        },
        "b0160": {
            "authors": [
                {
                    "first": "Diane M.",
                    "initial": "D.M.",
                    "last": "Harper"
                },
                {
                    "first": "Inge",
                    "initial": "I.",
                    "last": "Verdenius"
                },
                {
                    "first": "Felicia",
                    "initial": "F.",
                    "last": "Ratnaraj"
                },
                {
                    "first": "Anne M.",
                    "initial": "A.M.",
                    "last": "Arey"
                },
                {
                    "first": "Beth",
                    "initial": "B.",
                    "last": "Rosemergey"
                },
                {
                    "first": "Gerard J.",
                    "initial": "G.J.",
                    "last": "Malnar"
                },
                {
                    "first": "Jeffrey",
                    "initial": "J.",
                    "last": "Wall"
                }
            ],
            "doi": "10.1371/journal.pone.0077961",
            "issn": "19326203",
            "pmid": "24223131",
            "pub_year": 2013,
            "title": "Quantifying clinical HPV4 dose inefficiencies in a Safety Net Population",
            "volume": "8"
        },
        "b0165": {
            "authors": [
                {
                    "first": "Lauri E.",
                    "initial": "L.E.",
                    "last": "Markowitz"
                },
                {
                    "first": "Vivien",
                    "initial": "V.",
                    "last": "Tsu"
                },
                {
                    "first": "Shelley L.",
                    "initial": "S.L.",
                    "last": "Deeks"
                },
                {
                    "first": "Heather",
                    "initial": "H.",
                    "last": "Cubie"
                },
                {
                    "first": "Susan A.",
                    "initial": "S.A.",
                    "last": "Wang"
                },
                {
                    "first": "Andrea S.",
                    "initial": "A.S.",
                    "last": "Vicari"
                },
                {
                    "first": "Julia M.L.",
                    "initial": "J.M.L.",
                    "last": "Brotherton"
                }
            ],
            "doi": "10.1016/j.vaccine.2012.05.039",
            "firstpage": "F139",
            "issn": "0264410X",
            "lastpage": "F148",
            "pub_year": 2012,
            "title": "Human papillomavirus vaccine introduction - the first five years",
            "volume": "30"
        },
        "b0170": {
            "authors": [
                {
                    "first": "Tom Glass",
                    "initial": "T.G.",
                    "last": "Hopkins"
                },
                {
                    "first": "Nick",
                    "initial": "N.",
                    "last": "Wood"
                }
            ],
            "doi": "10.1016/j.vaccine.2013.01.028",
            "firstpage": "1673",
            "issn": "0264410X",
            "lastpage": "1679",
            "pmid": "23375978",
            "pub_year": 2013,
            "title": "Female human papillomavirus (HPV) vaccination: Global uptake and the impact of attitudes",
            "volume": "31"
        },
        "b0175": {
            "authors": [
                {
                    "first": "Diane M.",
                    "initial": "D.M.",
                    "last": "Harper"
                },
                {
                    "first": "Inge",
                    "initial": "I.",
                    "last": "Verdenius"
                },
                {
                    "first": "George D.",
                    "initial": "G.D.",
                    "last": "Harris"
                },
                {
                    "first": "Angela L.",
                    "initial": "A.L.",
                    "last": "Barnett"
                },
                {
                    "first": "Beth E.",
                    "initial": "B.E.",
                    "last": "Rosemergey"
                },
                {
                    "first": "Anne M.",
                    "initial": "A.M.",
                    "last": "Arey"
                },
                {
                    "first": "Jeffrey",
                    "initial": "J.",
                    "last": "Wall"
                },
                {
                    "first": "Gerard J.",
                    "initial": "G.J.",
                    "last": "Malnar"
                }
            ],
            "doi": "10.1016/j.ypmed.2014.01.007",
            "firstpage": "20",
            "issn": "00917435",
            "lastpage": "25",
            "pmid": "24440159",
            "pub_year": 2014,
            "title": "The influence of free quadrivalent human papillomavirus vaccine (HPV4) on the timely completion of the three dose series",
            "volume": "61"
        },
        "b0180": {
            "authors": [
                {
                    "first": "Francis J.",
                    "initial": "F.J.",
                    "last": "Dessy"
                },
                {
                    "first": "Sandra L.",
                    "initial": "S.L.",
                    "last": "Giannini"
                },
                {
                    "first": "Catherine A.",
                    "initial": "C.A.",
                    "last": "Bougelet"
                },
                {
                    "first": "Troy J.",
                    "initial": "T.J.",
                    "last": "Kemp"
                },
                {
                    "first": "Marie Pierre M.",
                    "initial": "M.P.M.",
                    "last": "David"
                },
                {
                    "first": "Sylviane M.",
                    "initial": "S.M.",
                    "last": "Poncelet"
                },
                {
                    "first": "Ligia A.",
                    "initial": "L.A.",
                    "last": "Pinto"
                },
                {
                    "first": "Martine A.",
                    "initial": "M.A.",
                    "last": "Wettendorff"
                }
            ],
            "doi": "10.4161/hv.4.6.6912",
            "firstpage": "425",
            "issn": "15548600",
            "lastpage": "434",
            "pmid": "18948732",
            "pub_year": 2008,
            "title": "Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine",
            "volume": "4"
        },
        "b0185": {
            "authors": [
                {
                    "first": "Eve",
                    "initial": "E.",
                    "last": "Draper"
                },
                {
                    "first": "Sara L.",
                    "initial": "S.L.",
                    "last": "Bissett"
                },
                {
                    "first": "Rebecca",
                    "initial": "R.",
                    "last": "Howell-Jones"
                },
                {
                    "first": "Pauline",
                    "initial": "P.",
                    "last": "Waight"
                },
                {
                    "first": "Kate",
                    "initial": "K.",
                    "last": "Soldan"
                },
                {
                    "first": "Mark",
                    "initial": "M.",
                    "last": "Jit"
                },
                {
                    "first": "Nicholas",
                    "initial": "N.",
                    "last": "Andrews"
                },
                {
                    "first": "Elizabeth",
                    "initial": "E.",
                    "last": "Miller"
                },
                {
                    "first": "Simon",
                    "initial": "S.",
                    "last": "Beddows"
                }
            ],
            "doi": "10.1371/journal.pone.0061825",
            "issn": "19326203",
            "pmid": "23650505",
            "pub_year": 2013,
            "title": "A Randomized, Observer-Blinded Immunogenicity Trial of Cervarix\u00ae and Gardasil\u00ae Human Papillomavirus Vaccines in 12-15 Year Old Girls",
            "volume": "8"
        },
        "b0190": {
            "authors": [
                {
                    "first": "Lars",
                    "initial": "L.",
                    "last": "Toft"
                },
                {
                    "first": "Merete",
                    "initial": "M.",
                    "last": "Storgaard"
                },
                {
                    "first": "Martin",
                    "initial": "M.",
                    "last": "M\u00fcller"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Sehr"
                },
                {
                    "first": "Jesper",
                    "initial": "J.",
                    "last": "Bonde"
                },
                {
                    "first": "Martin",
                    "initial": "M.",
                    "last": "Tolstrup"
                },
                {
                    "first": "Lars",
                    "initial": "L.",
                    "last": "\u00d8stergaard"
                },
                {
                    "first": "Ole S.",
                    "initial": "O.S.",
                    "last": "S\u00f8gaard"
                }
            ],
            "doi": "10.1093/infdis/jit657",
            "firstpage": "1165",
            "issn": "00221899",
            "lastpage": "1173",
            "pmid": "24273179",
            "pub_year": 2014,
            "title": "Comparison of the immunogenicity and reactogenicity of cervarix and gardasil human papillomavirus vaccines in HIV-Infected adults: A randomized, double-blind clinical trial",
            "volume": "209"
        },
        "b0195": {
            "authors": [
                {
                    "first": "Luisa",
                    "initial": "L.",
                    "last": "Barzon"
                },
                {
                    "first": "Laura",
                    "initial": "L.",
                    "last": "Squarzon"
                },
                {
                    "first": "Serena",
                    "initial": "S.",
                    "last": "Masiero"
                },
                {
                    "first": "Monia",
                    "initial": "M.",
                    "last": "Pacenti"
                },
                {
                    "first": "Giorgia",
                    "initial": "G.",
                    "last": "Marcati"
                },
                {
                    "first": "Barbara",
                    "initial": "B.",
                    "last": "Mantelli"
                },
                {
                    "first": "Liliana",
                    "initial": "L.",
                    "last": "Gabrielli"
                },
                {
                    "first": "Maria Grazia",
                    "initial": "M.G.",
                    "last": "Pascucci"
                },
                {
                    "first": "Tiziana",
                    "initial": "T.",
                    "last": "Lazzarotto"
                },
                {
                    "first": "Antonella",
                    "initial": "A.",
                    "last": "Caputo"
                },
                {
                    "first": "Giorgio",
                    "initial": "G.",
                    "last": "Pal\u00f9"
                }
            ],
            "doi": "10.1016/j.vaccine.2014.07.014",
            "firstpage": "5357",
            "issn": "0264410X",
            "lastpage": "5362",
            "pmid": "25045814",
            "pub_year": 2014,
            "title": "Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes",
            "volume": "32"
        },
        "b0200": {
            "authors": [
                {
                    "first": "Sandra L.",
                    "initial": "S.L.",
                    "last": "Giannini"
                },
                {
                    "first": "Emmanuel",
                    "initial": "E.",
                    "last": "Hanon"
                },
                {
                    "first": "Philippe",
                    "initial": "P.",
                    "last": "Moris"
                },
                {
                    "first": "Marcelle",
                    "initial": "M.",
                    "last": "Van Mechelen"
                },
                {
                    "first": "Sandra",
                    "initial": "S.",
                    "last": "Morel"
                },
                {
                    "first": "Francis",
                    "initial": "F.",
                    "last": "Dessy"
                },
                {
                    "first": "Marc A.",
                    "initial": "M.A.",
                    "last": "Fourneau"
                },
                {
                    "first": "Brigitte",
                    "initial": "B.",
                    "last": "Colau"
                },
                {
                    "first": "Joann",
                    "initial": "J.",
                    "last": "Suzich"
                },
                {
                    "first": "Genevieve",
                    "initial": "G.",
                    "last": "Losonksy"
                },
                {
                    "first": "Marie Th\u00e9r\u00e8se",
                    "initial": "M.T.",
                    "last": "Martin"
                },
                {
                    "first": "Gary",
                    "initial": "G.",
                    "last": "Dubin"
                },
                {
                    "first": "Martine A.",
                    "initial": "M.A.",
                    "last": "Wettendorff"
                }
            ],
            "doi": "10.1016/j.vaccine.2006.06.005",
            "firstpage": "5937",
            "issn": "0264410X",
            "lastpage": "5949",
            "pmid": "16828940",
            "pub_year": 2006,
            "title": "Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only",
            "volume": "24"
        },
        "b0205": {
            "authors": [
                {
                    "first": "Xavier",
                    "initial": "X.",
                    "last": "Castellsagu\u00e9"
                },
                {
                    "first": "Paulo",
                    "initial": "P.",
                    "last": "Naud"
                },
                {
                    "first": "Song Nan",
                    "initial": "S.N.",
                    "last": "Chow"
                },
                {
                    "first": "Cosette M.",
                    "initial": "C.M.",
                    "last": "Wheeler"
                },
                {
                    "first": "Maria Julieta V.",
                    "initial": "M.J.V.",
                    "last": "Germar"
                },
                {
                    "first": "Matti",
                    "initial": "M.",
                    "last": "Lehtinen"
                },
                {
                    "first": "Jorma",
                    "initial": "J.",
                    "last": "Paavonen"
                },
                {
                    "first": "Unnop",
                    "initial": "U.",
                    "last": "Jaisamrarn"
                },
                {
                    "first": "Suzanne M.",
                    "initial": "S.M.",
                    "last": "Garland"
                },
                {
                    "first": "Jorge",
                    "initial": "J.",
                    "last": "Salmer\u00f3n"
                },
                {
                    "first": "Dan",
                    "initial": "D.",
                    "last": "Apter"
                },
                {
                    "first": "Henry",
                    "initial": "H.",
                    "last": "Kitchener"
                },
                {
                    "first": "Julio C.",
                    "initial": "J.C.",
                    "last": "Teixeira"
                },
                {
                    "first": "S. Rachel",
                    "initial": "S.R.",
                    "last": "Skinner"
                },
                {
                    "first": "Genara",
                    "initial": "G.",
                    "last": "Limson"
                },
                {
                    "first": "Anne",
                    "initial": "A.",
                    "last": "Szarewski"
                },
                {
                    "first": "Barbara",
                    "initial": "B.",
                    "last": "Romanowski"
                },
                {
                    "first": "Fred Y.",
                    "initial": "F.Y.",
                    "last": "Aoki"
                },
                {
                    "first": "Tino F.",
                    "initial": "T.F.",
                    "last": "Schwarz"
                },
                {
                    "first": "Willy A.J.",
                    "initial": "W.A.J.",
                    "last": "Poppe"
                },
                {
                    "first": "F. Xavier",
                    "initial": "F.X.",
                    "last": "Bosch"
                },
                {
                    "first": "Newton S.",
                    "initial": "N.S.",
                    "last": "De Carvalho"
                },
                {
                    "first": "Klaus",
                    "initial": "K.",
                    "last": "Peters"
                },
                {
                    "first": "Wiebren A.A.",
                    "initial": "W.A.A.",
                    "last": "Tjalma"
                },
                {
                    "first": "Mahboobeh",
                    "initial": "M.",
                    "last": "Safaeian"
                },
                {
                    "first": "Alice",
                    "initial": "A.",
                    "last": "Raillard"
                },
                {
                    "first": "Dominique",
                    "initial": "D.",
                    "last": "Descamps"
                },
                {
                    "first": "Frank",
                    "initial": "F.",
                    "last": "Struyf"
                },
                {
                    "first": "Gary",
                    "initial": "G.",
                    "last": "Dubin"
                },
                {
                    "first": "Dominique",
                    "initial": "D.",
                    "last": "Rosillon"
                },
                {
                    "first": "Laurence",
                    "initial": "L.",
                    "last": "Baril"
                }
            ],
            "doi": "10.1093/infdis/jiu139",
            "firstpage": "517",
            "issn": "00221899",
            "lastpage": "534",
            "pmid": "24610876",
            "pub_year": 2014,
            "title": "Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: Analysis of the control arm of PATRICIA",
            "volume": "210"
        },
        "b0210": {
            "authors": [
                {
                    "first": "Mahboobeh",
                    "initial": "M.",
                    "last": "Safaeian"
                },
                {
                    "first": "Carolina",
                    "initial": "C.",
                    "last": "Porras"
                },
                {
                    "first": "Mark",
                    "initial": "M.",
                    "last": "Schiffman"
                },
                {
                    "first": "Ana Cecilia",
                    "initial": "A.C.",
                    "last": "Rodriguez"
                },
                {
                    "first": "Sholom",
                    "initial": "S.",
                    "last": "Wacholder"
                },
                {
                    "first": "Paula",
                    "initial": "P.",
                    "last": "Gonzalez"
                },
                {
                    "first": "Wim",
                    "initial": "W.",
                    "last": "Quint"
                },
                {
                    "first": "Leen Jan",
                    "initial": "L.J.",
                    "last": "Van Doorn"
                },
                {
                    "first": "Mark E.",
                    "initial": "M.E.",
                    "last": "Sherman"
                },
                {
                    "first": "Val\u00e9rie",
                    "initial": "V.",
                    "last": "Xhenseval"
                },
                {
                    "first": "Rolando",
                    "initial": "R.",
                    "last": "Herrero"
                },
                {
                    "first": "Allan",
                    "initial": "A.",
                    "last": "Hildesheim"
                }
            ],
            "doi": "10.1093/jnci/djq384",
            "firstpage": "1653",
            "issn": "00278874",
            "lastpage": "1662",
            "pub_year": 2010,
            "title": "Epidemiological study of Anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections",
            "volume": "102"
        },
        "b0215": {
            "authors": [
                {
                    "first": "Nadia L.",
                    "initial": "N.L.",
                    "last": "Bernasconi"
                },
                {
                    "first": "Elisabetta",
                    "initial": "E.",
                    "last": "Traggiai"
                },
                {
                    "first": "Antonio",
                    "initial": "A.",
                    "last": "Lanzavecchia"
                }
            ],
            "doi": "10.1126/science.1076071",
            "firstpage": "2199",
            "issn": "00368075",
            "lastpage": "2202",
            "pmid": "12481138",
            "pub_year": 2002,
            "title": "Maintenance of serological memory by polyclonal activation of human memory B cells",
            "volume": "298"
        },
        "b0220": {
            "authors": [
                {
                    "first": "Shane",
                    "initial": "S.",
                    "last": "Crotty"
                },
                {
                    "first": "Phil",
                    "initial": "P.",
                    "last": "Felgner"
                },
                {
                    "first": "Huw",
                    "initial": "H.",
                    "last": "Davies"
                },
                {
                    "first": "John",
                    "initial": "J.",
                    "last": "Glidewell"
                },
                {
                    "first": "Luis",
                    "initial": "L.",
                    "last": "Villarreal"
                },
                {
                    "first": "Rafi",
                    "initial": "R.",
                    "last": "Ahmed"
                }
            ],
            "doi": "10.4049/jimmunol.171.10.4969",
            "firstpage": "4969",
            "issn": "00221767",
            "lastpage": "4973",
            "pmid": "14607890",
            "pub_year": 2003,
            "title": "Cutting Edge: Long-Term B Cell Memory in Humans after Smallpox Vaccination",
            "volume": "171"
        },
        "b0225": {
            "authors": [
                {
                    "first": "Elisabetta",
                    "initial": "E.",
                    "last": "Traggiai"
                },
                {
                    "first": "Roberto",
                    "initial": "R.",
                    "last": "Puzone"
                },
                {
                    "first": "Antonio",
                    "initial": "A.",
                    "last": "Lanzavecchia"
                }
            ],
            "doi": "10.1016/S0264-410X(03)00198-1",
            "firstpage": "S35",
            "issn": "0264410X",
            "lastpage": "S37",
            "pmid": "12763680",
            "pub_year": 2003,
            "title": "Antigen dependent and independent mechanisms that sustain serum antibody levels",
            "volume": "21"
        },
        "b0230": {
            "authors": [
                {
                    "first": "Nathalie",
                    "initial": "N.",
                    "last": "Garon"
                },
                {
                    "first": "Sandra",
                    "initial": "S.",
                    "last": "Morel"
                },
                {
                    "first": "Arnaud",
                    "initial": "A.",
                    "last": "Didierlaurent"
                },
                {
                    "first": "Dominique",
                    "initial": "D.",
                    "last": "Descamps"
                },
                {
                    "first": "Martine",
                    "initial": "M.",
                    "last": "Wettendorff"
                },
                {
                    "first": "Marcelle",
                    "initial": "M.",
                    "last": "Van Mechelen"
                }
            ],
            "doi": "10.2165/11591760-000000000-00000",
            "firstpage": "217",
            "issn": "11738804",
            "lastpage": "226",
            "pmid": "21815697",
            "pub_year": 2011,
            "title": "Development of an AS04-adjuvanted HPV vaccine with the adjuvant system approach",
            "volume": "25"
        },
        "b0235": {
            "authors": [
                {
                    "first": "Douglas M.",
                    "initial": "D.M.",
                    "last": "Herrin"
                },
                {
                    "first": "Emily E.",
                    "initial": "E.E.",
                    "last": "Coates"
                },
                {
                    "first": "Pamela J.",
                    "initial": "P.J.",
                    "last": "Costner"
                },
                {
                    "first": "Troy J.",
                    "initial": "T.J.",
                    "last": "Kemp"
                },
                {
                    "first": "Martha C.",
                    "initial": "M.C.",
                    "last": "Nason"
                },
                {
                    "first": "Kapil K.",
                    "initial": "K.K.",
                    "last": "Saharia"
                },
                {
                    "first": "Yuanji",
                    "initial": "Y.",
                    "last": "Pan"
                },
                {
                    "first": "Uzma N.",
                    "initial": "U.N.",
                    "last": "Sarwar"
                },
                {
                    "first": "Lasonji",
                    "initial": "L.",
                    "last": "Holman"
                },
                {
                    "first": "Galina",
                    "initial": "G.",
                    "last": "Yamshchikov"
                },
                {
                    "first": "Richard A.",
                    "initial": "R.A.",
                    "last": "Koup"
                },
                {
                    "first": "Yuk Ying S.",
                    "initial": "Y.Y.S.",
                    "last": "Pang"
                },
                {
                    "first": "Robert A.",
                    "initial": "R.A.",
                    "last": "Seder"
                },
                {
                    "first": "John T.",
                    "initial": "J.T.",
                    "last": "Schiller"
                },
                {
                    "first": "Barney S.",
                    "initial": "B.S.",
                    "last": "Graham"
                },
                {
                    "first": "Ligia A.",
                    "initial": "L.A.",
                    "last": "Pinto"
                },
                {
                    "first": "Julie E.",
                    "initial": "J.E.",
                    "last": "Ledgerwood"
                }
            ],
            "doi": "10.4161/hv.34408",
            "firstpage": "3446",
            "issn": "21645515",
            "lastpage": "3454",
            "pmid": "25483691",
            "pub_year": 2014,
            "title": "Comparison of adaptive and innate immune responses induced by licensed vaccines for human papillomavirus",
            "volume": "10"
        },
        "b0240": null,
        "b0245": {
            "authors": [
                {
                    "first": "Mirte",
                    "initial": "M.",
                    "last": "Scherpenisse"
                },
                {
                    "first": "Rutger M.",
                    "initial": "R.M.",
                    "last": "Schepp"
                },
                {
                    "first": "Madelief",
                    "initial": "M.",
                    "last": "Mollers"
                },
                {
                    "first": "Chris J.L.M.",
                    "initial": "C.J.L.M.",
                    "last": "Meijer"
                },
                {
                    "first": "Guy A.M.",
                    "initial": "G.A.M.",
                    "last": "Berbers"
                },
                {
                    "first": "Fiona R.M.",
                    "initial": "F.R.M.",
                    "last": "van der Klis"
                }
            ],
            "doi": "10.1371/journal.pone.0074797",
            "issn": "19326203",
            "pmid": "24058629",
            "pub_year": 2013,
            "title": "Characteristics of HPV-Specific Antibody Responses Induced by Infection and Vaccination: Cross-Reactivity, Neutralizing Activity, Avidity and IgG Subclasses",
            "volume": "8"
        },
        "b0250": {
            "authors": [
                {
                    "first": "Maria Genalin",
                    "initial": "M.G.",
                    "last": "Angelo"
                },
                {
                    "first": "Marie Pierre",
                    "initial": "M.P.",
                    "last": "David"
                },
                {
                    "first": "Julia",
                    "initial": "J.",
                    "last": "Zima"
                },
                {
                    "first": "Laurence",
                    "initial": "L.",
                    "last": "Baril"
                },
                {
                    "first": "Gary",
                    "initial": "G.",
                    "last": "Dubin"
                },
                {
                    "first": "Felix",
                    "initial": "F.",
                    "last": "Arellano"
                },
                {
                    "first": "Frank",
                    "initial": "F.",
                    "last": "Struyf"
                }
            ],
            "doi": "10.1002/pds.3554",
            "firstpage": "466",
            "issn": "10538569",
            "lastpage": "479",
            "pmid": "24644063",
            "pub_year": 2014,
            "title": "Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme",
            "volume": "23"
        },
        "b0255": {
            "authors": [
                {
                    "first": "Maria Genalin",
                    "initial": "M.G.",
                    "last": "Angelo"
                },
                {
                    "first": "Julia",
                    "initial": "J.",
                    "last": "Zima"
                },
                {
                    "first": "Fernanda",
                    "initial": "F.",
                    "last": "Tavares Da Silva"
                },
                {
                    "first": "Laurence",
                    "initial": "L.",
                    "last": "Baril"
                },
                {
                    "first": "Felix",
                    "initial": "F.",
                    "last": "Arellano"
                }
            ],
            "doi": "10.1002/pds.3593",
            "firstpage": "456",
            "issn": "10538569",
            "lastpage": "465",
            "pmid": "24644078",
            "pub_year": 2014,
            "title": "Post-licensure safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vaccine: More than 4years of experience",
            "volume": "23"
        },
        "b0260": {
            "authors": [
                {
                    "first": "Stan L.",
                    "initial": "S.L.",
                    "last": "Block"
                },
                {
                    "first": "Darron R.",
                    "initial": "D.R.",
                    "last": "Brown"
                },
                {
                    "first": "Archana",
                    "initial": "A.",
                    "last": "Chatterjee"
                },
                {
                    "first": "Michael A.",
                    "initial": "M.A.",
                    "last": "Gold"
                },
                {
                    "first": "Heather L.",
                    "initial": "H.L.",
                    "last": "Sings"
                },
                {
                    "first": "Anne",
                    "initial": "A.",
                    "last": "Meibohm"
                },
                {
                    "first": "Adrian",
                    "initial": "A.",
                    "last": "Dana"
                },
                {
                    "first": "Richard M.",
                    "initial": "R.M.",
                    "last": "Haupt"
                },
                {
                    "first": "Eliav",
                    "initial": "E.",
                    "last": "Barr"
                },
                {
                    "first": "Gretchen M.",
                    "initial": "G.M.",
                    "last": "Tamms"
                },
                {
                    "first": "Haiping",
                    "initial": "H.",
                    "last": "Zhou"
                },
                {
                    "first": "Keith S.",
                    "initial": "K.S.",
                    "last": "Reisinger"
                }
            ],
            "doi": "10.1097/INF.0b013e3181b77906",
            "firstpage": "95",
            "issn": "08913668",
            "lastpage": "101",
            "pub_year": 2010,
            "title": "Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (Types 6, 11, 16, and 18) L1 virus-like particle vaccine",
            "volume": "29"
        }
    },
    "body_text": [
        {
            "endOffset": 21435,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 21434,
                    "startOffset": 21431
                }
            },
            "secId": "s0005",
            "sentence": "Both vaccines contain L1 virus-like particles (VLPs) from the two oncogenic HPV types most prevalent in cervical cancer, i.e. HPV-16 and HPV-18 [1].",
            "startOffset": 21287,
            "title": "Introduction"
        },
        {
            "endOffset": 25606,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "In pre-selected sites, the first 50 subjects from each age stratum in each group (300) were assigned to the cell-mediated immunity (CMI) sub-cohort for measurement of circulating HPV-specific B- and T-lymphocytes.",
            "startOffset": 25393,
            "title": "Vaccines, randomization and masking"
        },
        {
            "endOffset": 30716,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Assuming that 20% of subjects would withdraw or would not be evaluable for immunogenicity 1 M after the last dose, the target sample size for enrolment was 1074 subjects (358/group).",
            "startOffset": 30534,
            "title": "Statistical methods"
        },
        {
            "endOffset": 28033,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "refoffsets": {
                "b0085": {
                    "endOffset": 28032,
                    "startOffset": 28022
                },
                "b0130": {
                    "endOffset": 28032,
                    "startOffset": 28022
                },
                "b0135": {
                    "endOffset": 28032,
                    "startOffset": 28022
                },
                "b0140": {
                    "endOffset": 28032,
                    "startOffset": 28022
                }
            },
            "secId": "s0030",
            "sentence": "Flow cytometry was then used to quantify number of lymphocytes producing at least 2 out of the 4 different immune markers assessed [17,26\u201328].",
            "startOffset": 27891,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 32796,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "refoffsets": {
                "b0120": {
                    "endOffset": 32795,
                    "startOffset": 32791
                }
            },
            "secId": "s0055",
            "sentence": "The primary objective and results up to M12 were described previously [24].",
            "startOffset": 32721,
            "title": "Immunological non-inferiority and superiority"
        },
        {
            "endOffset": 26468,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "In this procedure, assay cut-off is 40 ED50 (effective dose producing 50% response, for each antigen).",
            "startOffset": 26366,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 29715,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Non-inferiority in terms of geometric mean antibody titers (GMT) was shown if, for both, the upper limits of the 95% CIs for the GMT ratios (2D or 3D 4vHPV divided by 2D AS04-HPV-16/18 vaccine) were below 2.",
            "startOffset": 29508,
            "title": "Statistical methods"
        },
        {
            "endOffset": 26597,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "refoffsets": {
                "b0120": {
                    "endOffset": 26596,
                    "startOffset": 26592
                }
            },
            "secId": "s0030",
            "sentence": "The frequencies of HPV-specific memory B-lymphocytes were measured by using standard enzyme-linked immunosorbent spot assay [24].",
            "startOffset": 26468,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 30827,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Seroconversion, seropositivity rates and GMTs for HPV-16/-18 antibodies were calculated by baseline serostatus.",
            "startOffset": 30716,
            "title": "Statistical methods"
        },
        {
            "endOffset": 21868,
            "parents": [],
            "secId": "s0005",
            "sentence": "More recently, a nonvalent vaccine was licensed using the same HPV-6, -11, -16 and -18 antigens as the four-valent vaccine and VLPs for 5 additional oncogenic HPV types (Gardasil 9, Merck & Co.",
            "startOffset": 21675,
            "title": "Introduction"
        },
        {
            "endOffset": 21609,
            "parents": [],
            "secId": "s0005",
            "sentence": "The main differences in the composition of both vaccines are the inclusion of HPV-6 and -11 L1 VLPs in the 4vHPV vaccine and the AS04 adjuvantation in the HPV-16/18 vaccine.",
            "startOffset": 21436,
            "title": "Introduction"
        },
        {
            "endOffset": 29909,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "If non-inferiority was demonstrated and lower limits of the two-sided 95% CIs for the ratio of GMTs of a given antigen were above 1 in the ATP, superiority was assessed sequentially in the TVC.",
            "startOffset": 29716,
            "title": "Statistical methods"
        },
        {
            "endOffset": 25905,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "An additional blood sample was taken from girls assigned to the subset.",
            "startOffset": 25834,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 23474,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The study was observer-blind, randomized and age-stratified with three parallel groups (Fig. 1) conducted at 21 sites in France, Hong Kong, Singapore and Sweden (November 2011 to October 2015).",
            "startOffset": 23281,
            "title": "Study design and ethics"
        },
        {
            "endOffset": 32101,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Statistical analyses were performed using SAS 9.2 and PROC StatXact 8.1.",
            "startOffset": 32029,
            "title": "Statistical methods"
        },
        {
            "endOffset": 41296,
            "parents": [],
            "refoffsets": {
                "b0230": {
                    "endOffset": 41295,
                    "startOffset": 41291
                }
            },
            "secId": "s0075",
            "sentence": "The enhanced CD4+ T-cell response observed in the AS04-HPV-16/18 group may be related to the ability of the monophosphoryl lipid A component of the AS04 adjuvant to enhance antigen presentation to CD4+ T cells, resulting in turn in increased differentiation of B cells into antibody-producing plasma cells and memory B cells [46].",
            "startOffset": 40966,
            "title": "Discussion"
        },
        {
            "endOffset": 26273,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "refoffsets": {
                "b0005": {
                    "endOffset": 26272,
                    "startOffset": 26266
                },
                "b0115": {
                    "endOffset": 26272,
                    "startOffset": 26266
                }
            },
            "secId": "s0030",
            "sentence": "Neutralizing HPV-16/-18 antibodies were determined by PBNA [1,23].",
            "startOffset": 26207,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 33152,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "For the 2D AS04-HPV-16/18 vs. 2D 4vHPV comparisons, superiority was shown in terms of GMT ratios, confirming that the 2D AS04-HPV-16/18 elicited antibody titers at M36 that were more than two and sixfold higher for anti-HPV-16 (2.78) and anti-HPV-18 (6.84), respectively (Table 2).",
            "startOffset": 32871,
            "title": "Immunological non-inferiority and superiority"
        },
        {
            "endOffset": 35829,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "refoffsets": {
                "b0130": {
                    "endOffset": 35828,
                    "startOffset": 35824
                }
            },
            "secId": "s0070",
            "sentence": "Solicited or unsolicited AEs and potential immune-mediated disease (pIMDs) up to M12 were reported previously [26].",
            "startOffset": 35714,
            "title": "Safety"
        },
        {
            "endOffset": 34684,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "HPV-16/18 GMTs, which had reached a peak response at M7, gradually declined up to M36 in all three groups.",
            "startOffset": 34578,
            "title": "Antibody responses"
        },
        {
            "endOffset": 28825,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "For superiority testing, the total vaccinated cohort (TVC) (with at least one documented vaccine dose), was used as the primary analysis set because it tends to avoid over-optimistic estimates of efficacy resulting from a per protocol analysis, since the non-compliers included in the full analysis set will generally diminish the estimated treatment effect.",
            "startOffset": 28467,
            "title": "Statistical methods"
        },
        {
            "endOffset": 27504,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "The frequencies of HPV-16 and -18-specific CD4+ and CD8+ T-lymphocytes were evaluated using a standard Intracellular Cytokine Staining assay.",
            "startOffset": 27363,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 32028,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Statistical testing was not planned or conducted for safety and inferences were based on descriptive comparisons.",
            "startOffset": 31915,
            "title": "Statistical methods"
        },
        {
            "endOffset": 24904,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Enrolment was stratified by age (approximately 50% aged 9-11y and 50% aged 12-14y), and girls were randomized (1:1:1 ratio in each age stratum) to receive either 2D AS04-HPV-16/18 (at M0,6, 2D HPV-6/11/16/18 at M0,6 or 3D HPV-6/11/16/18 at M0,2,6, in the deltoid muscle of the non-dominant arm.",
            "startOffset": 24610,
            "title": "Vaccines, randomization and masking"
        },
        {
            "endOffset": 28466,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "refoffsets": {
                "b0150": {
                    "endOffset": 28465,
                    "startOffset": 28461
                }
            },
            "secId": "s0040",
            "sentence": "The most conservative dataset was chosen for each analysis [30].",
            "startOffset": 28402,
            "title": "Statistical methods"
        },
        {
            "endOffset": 38108,
            "parents": [],
            "refoffsets": {
                "b0145": {
                    "endOffset": 38107,
                    "startOffset": 38100
                },
                "b0180": {
                    "endOffset": 38107,
                    "startOffset": 38100
                }
            },
            "secId": "s0075",
            "sentence": "The PBNA results were very similar to the results obtained using ELISA, as previously described, with strong correlation between ELISA and PNBA detection of anti-HPV-16/18 antibodies after vaccination [29,36].",
            "startOffset": 37899,
            "title": "Discussion"
        },
        {
            "endOffset": 34955,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "HPV-18 antibodies fell below the plateau at M12 with the 2D regimen and, by M18, with the 3D 4vHPV.",
            "startOffset": 34856,
            "title": "Antibody responses"
        },
        {
            "endOffset": 25833,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Blood was sampled at M0 (pre-vaccination) and at M7, 12, 18, 24 and 36 for the measurement of HPV-16/-18 antibodies by ELISA and PBNA in a subset.",
            "startOffset": 25687,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 37642,
            "parents": [],
            "secId": "s0075",
            "sentence": "We found that anti-HPV-16/-18 GMTs, as measured by ELISA, were still significantly higher 30 M after the last vaccine dose following administration of 2D AS04-HPV-16/18 vaccine vs. 2D and 3D 4vHPV vaccine.",
            "startOffset": 37437,
            "title": "Discussion"
        },
        {
            "endOffset": 27363,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Finally, plates were dried overnight before analysis using an automated counting spot system (Axiovision).",
            "startOffset": 27257,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 39340,
            "parents": [],
            "refoffsets": {
                "b0205": {
                    "endOffset": 39339,
                    "startOffset": 39332
                },
                "b0210": {
                    "endOffset": 39339,
                    "startOffset": 39332
                }
            },
            "secId": "s0075",
            "sentence": "An immunological correlate of protection has not yet been defined for HPV infection and associated cervical lesions, although previous studies have shown that higher titers of naturally-acquired HPV-16 antibodies (by ELISA) and, to a lesser extent HPV-18 antibodies, were associated with lower risk of newly detected infection and cervical abnormalities caused by the same HPV type in unvaccinated subjects [41,42].",
            "startOffset": 38925,
            "title": "Discussion"
        },
        {
            "endOffset": 24970,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "refoffsets": {
                "b0005": {
                    "endOffset": 24969,
                    "startOffset": 24966
                }
            },
            "secId": "s0025",
            "sentence": "Compositions of both vaccines have been described previously [1].",
            "startOffset": 24905,
            "title": "Vaccines, randomization and masking"
        },
        {
            "endOffset": 34313,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Similar results were obtained by PBNA in the M36 ATP cohort for immunogenicity since all initially seronegative subjects (100%) from the 2D AS04-HPV-16/18 and 2D or 3D 4vHPV groups were still seroconverted for anti-HPV-16 neutralizing antibodies at study end.",
            "startOffset": 34054,
            "title": "Antibody responses"
        },
        {
            "endOffset": 28986,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "However, in an equivalence or non-inferiority trial use of the full analysis set is generally not conservative and its role should be considered very carefully.",
            "startOffset": 28826,
            "title": "Statistical methods"
        },
        {
            "endOffset": 39998,
            "parents": [],
            "refoffsets": {
                "b0040": {
                    "endOffset": 39997,
                    "startOffset": 39994
                }
            },
            "secId": "s0075",
            "sentence": "In those girls who received AS04-HPV-16/18, GMTs at M36 were above the plateau level of antibodies observed in women aged 15-25y participating in an efficacy trial, in whom sustained protection against HPV-16/18-associated infection and cervical lesions was shown [8].",
            "startOffset": 39730,
            "title": "Discussion"
        },
        {
            "endOffset": 31861,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "The plateau level is not used for clinical management of subjects.",
            "startOffset": 31795,
            "title": "Statistical methods"
        },
        {
            "endOffset": 29282,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "The ATP included subjects who received planned vaccine doses, met all eligibility criteria, complied with all requirements and for whom immunogenicity data were available.",
            "startOffset": 29111,
            "title": "Statistical methods"
        },
        {
            "endOffset": 24153,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Secondary objectives included evaluation of the non-inferiority/superiority of 2D AS04-HPV-16/18 vs. 2D and 3D 4vHPV at all subsequent time points until study conclusion (M36).",
            "startOffset": 23977,
            "title": "Study design and ethics"
        },
        {
            "endOffset": 42536,
            "parents": [],
            "secId": "s0075",
            "sentence": "Although there is no defined correlate of protection for HPV, the higher immune response observed following vaccination with AS04-HPV-16/18 may be indicative of a longer duration of protection.",
            "startOffset": 42343,
            "title": "Discussion"
        },
        {
            "endOffset": 32870,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Non-inferiority/superiority was also successfully demonstrated up to M36.",
            "startOffset": 32797,
            "title": "Immunological non-inferiority and superiority"
        },
        {
            "endOffset": 30379,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "For the non-inferiority analysis, 285 evaluable subjects/group in ATP would allow the detection of a 5% difference in anti-HPV-16/-18 seroconversion rates 1 M after the last dose with 95% power and the detection of a 2-fold difference in anti-HPV-16/-18 GMTs with at least 99% power.",
            "startOffset": 30096,
            "title": "Statistical methods"
        },
        {
            "endOffset": 26365,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "refoffsets": {
                "b0110": {
                    "endOffset": 26364,
                    "startOffset": 26360
                }
            },
            "secId": "s0030",
            "sentence": "Pseudovirions were produced independent of vaccine constructs as described previously [22].",
            "startOffset": 26274,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 36777,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "A total of 219 subjects reported at least one Medically Significant Condition up to M36, 77 of whom were in the 2D AS04-HPV-16/18 group, 79 in the 2D 4vHPV and 63 in the 3D 4vHPV in the TVC (Table 3).",
            "startOffset": 36577,
            "title": "Safety"
        },
        {
            "endOffset": 29507,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Non-inferiority in terms of seroconversion was shown if, for both anti-HPV-16 and -18, the upper limits of the 95% confidence intervals (CI) for the differences (2D or 3D 4vHPV minus 2D AS04-HPV-16/18 vaccine) were below 5%.",
            "startOffset": 29283,
            "title": "Statistical methods"
        },
        {
            "endOffset": 41794,
            "parents": [],
            "refoffsets": {
                "b0250": {
                    "endOffset": 41793,
                    "startOffset": 41786
                },
                "b0255": {
                    "endOffset": 41793,
                    "startOffset": 41786
                },
                "b0260": {
                    "endOffset": 41793,
                    "startOffset": 41786
                }
            },
            "secId": "s0075",
            "sentence": "Both vaccines had a clinically acceptable safety profile in this population, which is in line with the known safety profile observed in previous studies [50\u201352].",
            "startOffset": 41633,
            "title": "Discussion"
        },
        {
            "endOffset": 25393,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "The randomization code was generated using MATEX, a program developed for use in SAS (Cary, NC, USA), by GSK, Belgium.",
            "startOffset": 25275,
            "title": "Vaccines, randomization and masking"
        },
        {
            "endOffset": 22110,
            "parents": [],
            "secId": "s0005",
            "sentence": "However, high vaccine coverage and compliance rates proved to be difficult to achieve with a 3-dose (3D) regimen.",
            "startOffset": 21997,
            "title": "Introduction"
        },
        {
            "endOffset": 22403,
            "parents": [],
            "refoffsets": {
                "b0080": {
                    "endOffset": 22402,
                    "startOffset": 22398
                }
            },
            "secId": "s0005",
            "sentence": "WHO started recommending a 2D in young girls from 2014 [16].",
            "startOffset": 22343,
            "title": "Introduction"
        },
        {
            "endOffset": 30533,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "A sample size of 322 subjects/group in TVC would allow the demonstration of superiority in terms of GMTs 1 M after the last dose with at least 99% power.",
            "startOffset": 30380,
            "title": "Statistical methods"
        },
        {
            "endOffset": 26071,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "refoffsets": {
                "b0035": {
                    "endOffset": 26070,
                    "startOffset": 26064
                },
                "b0110": {
                    "endOffset": 26070,
                    "startOffset": 26064
                }
            },
            "secId": "s0030",
            "sentence": "Anti-HPV-16/-18 antibodies were determined by ELISA using the purified type-specific recombinant VLPs present in the AS04-HPV-16/18 vaccine as coating antigen [7,22].",
            "startOffset": 25905,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 22692,
            "parents": [],
            "refoffsets": {
                "b0085": {
                    "endOffset": 22691,
                    "startOffset": 22684
                },
                "b0090": {
                    "endOffset": 22691,
                    "startOffset": 22684
                },
                "b0095": {
                    "endOffset": 22691,
                    "startOffset": 22684
                },
                "b0100": {
                    "endOffset": 22691,
                    "startOffset": 22684
                },
                "b0105": {
                    "endOffset": 22691,
                    "startOffset": 22684
                }
            },
            "secId": "s0005",
            "sentence": "Superiority in terms of neutralizing antibody titers after vaccination with Cervarix compared to Gardasil was previously demonstrated in adult women with the standard 3D schedule [17\u201321].",
            "startOffset": 22505,
            "title": "Introduction"
        },
        {
            "endOffset": 32673,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "For all cohorts, the majority of girls in each group were seronegative for anti-HPV-16 and anti-HPV-18 at baseline (Table 1).",
            "startOffset": 32548,
            "title": "Study population"
        },
        {
            "endOffset": 37290,
            "parents": [],
            "refoffsets": {
                "b0160": {
                    "endOffset": 37289,
                    "startOffset": 37282
                },
                "b0165": {
                    "endOffset": 37289,
                    "startOffset": 37282
                },
                "b0170": {
                    "endOffset": 37289,
                    "startOffset": 37282
                },
                "b0175": {
                    "endOffset": 37289,
                    "startOffset": 37282
                }
            },
            "secId": "s0075",
            "sentence": "This may also help improve the relatively low vaccine coverage and series completion rates observed in some higher-income countries [32\u201335].",
            "startOffset": 37150,
            "title": "Discussion"
        },
        {
            "endOffset": 23636,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The trial is registered with ClinicalTrials.gov (NCT01462357) and conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines.",
            "startOffset": 23475,
            "title": "Study design and ethics"
        },
        {
            "endOffset": 23976,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The primary objective was to evaluate if immunogenicity to HPV-16 and -18, as measured by enzyme-linked immunosorbent assay (ELISA), of a 2D AS04-HPV-16/18 vaccine was non-inferior/superior to a 2D 4vHPV vaccine 1 M after the last vaccine dose (M7).",
            "startOffset": 23727,
            "title": "Study design and ethics"
        },
        {
            "endOffset": 34578,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "For HPV-18, all initially seronegative subjects (100%) from the AS04-HPV-16/18 group were still seroconverted at study end, while 13.8% of subjects in the 2D 4vHPV group and 5.5% of subjects in the 3D 4vHPV group had antibody titers below the assay cut-off at M36.",
            "startOffset": 34314,
            "title": "Antibody responses"
        },
        {
            "endOffset": 36162,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "Up to M36, a total of 46 subjects including 21 from the 2D AS04-HPV-16/18, 11 from the 2D 4vHPV and 14 from the 3D 4vHPV groups, reported at least one SAE (Table 3).",
            "startOffset": 35997,
            "title": "Safety"
        },
        {
            "endOffset": 30056,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Superiority was demonstrated if lower limit of the 95% CI for the ratio of GMTs (2D AS04-HPV-16/18 vaccine divided by 2D or 3D 4vHPV) was above 1.",
            "startOffset": 29910,
            "title": "Statistical methods"
        },
        {
            "endOffset": 33788,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "At M36, all initially seronegative subjects (100%) from the 2D AS04-HPV-16/18 group and nearly all subjects from the 2D (99.3%) and 3D (99.7%) 4vHPV groups had seroconverted for anti-HPV-16 antibodies when measured by ELISA.",
            "startOffset": 33564,
            "title": "Antibody responses"
        },
        {
            "endOffset": 42644,
            "parents": [],
            "secId": "s0080",
            "sentence": "Gardasil is a trademark of Merck & Co., Inc.",
            "startOffset": 42600,
            "title": "Trademarks"
        },
        {
            "endOffset": 28258,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "It presents the data for serious adverse events (SAEs) and medically significant adverse events (AEs) up to M36.",
            "startOffset": 28146,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 22504,
            "parents": [],
            "secId": "s0005",
            "sentence": "The mechanism of protection against mucosal infection is essentially thought to be antibody-mediated.",
            "startOffset": 22403,
            "title": "Introduction"
        },
        {
            "endOffset": 41633,
            "parents": [],
            "refoffsets": {
                "b0235": {
                    "endOffset": 41350,
                    "startOffset": 41346
                },
                "b0240": {
                    "endOffset": 41533,
                    "startOffset": 41526
                },
                "b0245": {
                    "endOffset": 41533,
                    "startOffset": 41526
                }
            },
            "secId": "s0075",
            "sentence": "Even if human studies, including ours and others [47], only show limited differences in vaccine-induced T-cell cytokine profiles between vaccines, there seem to be differences in the isotype switching of vaccine-induced antibody [48,49], which may correlate with differences in the quality of vaccine-induced adaptive cellular immunity.",
            "startOffset": 41297,
            "title": "Discussion"
        },
        {
            "endOffset": 32395,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Overall, 958 (89%) girls were included in the ATP cohort for immunogenicity at M36.",
            "startOffset": 32312,
            "title": "Study population"
        },
        {
            "endOffset": 36918,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "In addition, one case of pregnancy, which was electively terminated with no apparent congenital anomaly, was reported in the 3D 4vHPV group.",
            "startOffset": 36778,
            "title": "Safety"
        },
        {
            "endOffset": 21996,
            "parents": [],
            "refoffsets": {
                "b0035": {
                    "endOffset": 21995,
                    "startOffset": 21989
                },
                "b0040": {
                    "endOffset": 21995,
                    "startOffset": 21989
                },
                "b0045": {
                    "endOffset": 21995,
                    "startOffset": 21989
                },
                "b0050": {
                    "endOffset": 21995,
                    "startOffset": 21989
                },
                "b0055": {
                    "endOffset": 21995,
                    "startOffset": 21989
                },
                "b0060": {
                    "endOffset": 21995,
                    "startOffset": 21989
                },
                "b0065": {
                    "endOffset": 21995,
                    "startOffset": 21989
                }
            },
            "secId": "s0005",
            "sentence": "The initially licensed schedule for the HPV vaccines comprised 3 doses administered at months (M) 0, 1 or 2, and 6 [7\u201313].",
            "startOffset": 21874,
            "title": "Introduction"
        },
        {
            "endOffset": 35705,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Similar results were observed in the TVC regardless of the baseline serostatus.",
            "startOffset": 35626,
            "title": "Cell-mediated immunity"
        },
        {
            "endOffset": 42156,
            "parents": [],
            "secId": "s0075",
            "sentence": "A limitation of the study is the absence of a virological or clinical endpoint to assess potential differences in terms of protection against HPV infections or lesions.",
            "startOffset": 41988,
            "title": "Discussion"
        },
        {
            "endOffset": 35625,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "As observed at previous time points, HPV-16 and HPV-18 specific CD8+ T cells responses were undetectable (up to 4.0 cells/million CD8+ T cells) in all groups at M36.",
            "startOffset": 35460,
            "title": "Cell-mediated immunity"
        },
        {
            "endOffset": 20987,
            "parents": [],
            "refoffsets": {
                "b0015": {
                    "endOffset": 20986,
                    "startOffset": 20981
                },
                "b0020": {
                    "endOffset": 20986,
                    "startOffset": 20981
                },
                "b0025": {
                    "endOffset": 20986,
                    "startOffset": 20981
                },
                "b0030": {
                    "endOffset": 20986,
                    "startOffset": 20981
                },
                "b0035": {
                    "endOffset": 20986,
                    "startOffset": 20981
                }
            },
            "secId": "s0005",
            "sentence": "Human papillomavirus (HPV)-16 and HPV-18 are responsible for approximately 70% of cervical cancer cases [3\u20137].",
            "startOffset": 20877,
            "title": "Introduction"
        },
        {
            "endOffset": 37746,
            "parents": [],
            "secId": "s0075",
            "sentence": "The ELISA assay used as primary readout in this trial is based on VLPs from the AS04-HPV-16/18 vaccine.",
            "startOffset": 37643,
            "title": "Discussion"
        },
        {
            "endOffset": 25274,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Girls from the 2D groups received placebo [Al (OH)3] at M2 to maintain the blinding.",
            "startOffset": 25190,
            "title": "Vaccines, randomization and masking"
        },
        {
            "endOffset": 20876,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 20875,
                    "startOffset": 20870
                },
                "b0010": {
                    "endOffset": 20875,
                    "startOffset": 20870
                }
            },
            "secId": "s0005",
            "sentence": "Cervical cancer is one of the most frequent cancers in women throughout the World [1,2].",
            "startOffset": 20788,
            "title": "Introduction"
        },
        {
            "endOffset": 26831,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Briefly, peripheral blood mononuclear cells (PBMC) from clinical trial subjects were stimulated with oligonucleotide containing Cytosine phosphate Guanine motives during 5 days to induce differentiation into antibody secreting cells.",
            "startOffset": 26598,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 25189,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "The study was observer-blind.",
            "startOffset": 25160,
            "title": "Vaccines, randomization and masking"
        },
        {
            "endOffset": 32547,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "All groups were well matched with regard to demographic data (Table 1).",
            "startOffset": 32476,
            "title": "Study population"
        },
        {
            "endOffset": 36341,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "None of the SAEs were considered by the investigator to be vaccine-related.",
            "startOffset": 36266,
            "title": "Safety"
        },
        {
            "endOffset": 37149,
            "parents": [],
            "secId": "s0075",
            "sentence": "The recent licensure of 2D schedules of the HPV vaccines for preteens/adolescents is important for global public health, as this is likely to facilitate the introduction of vaccination programs in lower-income countries.",
            "startOffset": 36929,
            "title": "Discussion"
        },
        {
            "endOffset": 36265,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "One vaccine-unrelated case of fatal SAE (committed suicide) was recorded at M36 in the 3D 4vHPV group.",
            "startOffset": 36163,
            "title": "Safety"
        },
        {
            "endOffset": 37436,
            "parents": [],
            "secId": "s0075",
            "sentence": "This trial was undertaken to assess the immunogenicity and safety of a 2D AS04-HPV-16/18 vaccine vs. 2D and 3D 4vHPV vaccine in girls aged 9-14y.",
            "startOffset": 37291,
            "title": "Discussion"
        },
        {
            "endOffset": 25658,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "The same subjects were included in the PBNA subset.",
            "startOffset": 25607,
            "title": "Vaccines, randomization and masking"
        },
        {
            "endOffset": 27256,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Activated memory B-cells were then incubated overnight on plate, and spot forming cells were detected on day 6 by the addition of secondary antibody, conjugate complex and substrate.",
            "startOffset": 27074,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 21286,
            "parents": [],
            "refoffsets": {
                "b0040": {
                    "endOffset": 21028,
                    "startOffset": 21022
                },
                "b0045": {
                    "endOffset": 21028,
                    "startOffset": 21022
                },
                "b0050": {
                    "endOffset": 21028,
                    "startOffset": 21022
                }
            },
            "secId": "s0005",
            "sentence": "HPV vaccination began in 2006/2007 [8\u201310] when the first two HPV vaccines, the HPV-16/18 AS04-adjuvanted (AS04-HPV-16/18) vaccine (Cervarix, GSK) and the HPV6/11/16/18 (4vHPV) vaccine (Gardasil, Merck & Co., Inc.) were licensed for the prevention of cervical cancer and high-grade precursor lesions.",
            "startOffset": 20987,
            "title": "Introduction"
        },
        {
            "endOffset": 33563,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "In each group, all initially seronegative subjects from the ATP cohort had seroconverted for HPV-16/-18 antibodies at M7 when measured by ELISA and PBNA.",
            "startOffset": 33410,
            "title": "Antibody responses"
        },
        {
            "endOffset": 32311,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "A total of 1075 girls aged 9-14y received at least one vaccine dose (359 for 2D AS04-HPV-16/18, 358 for 2D 4vHPV, 358 for 3D 4vHPV) and 1036 (96%) completed the study to M36 (Fig. 1).",
            "startOffset": 32128,
            "title": "Study population"
        },
        {
            "endOffset": 26206,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Seronegativity corresponded to a titer lower than assay cut-off (19 ELISA units [EU]/mL for anti-HPV-16 and 18 EU/mL for anti-HPV-18).",
            "startOffset": 26072,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 27656,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Briefly, PBMC from clinical trial subjects were stimulated overnight with a pool of peptides covering the entire sequence of L1 antigens from HPV16/18.",
            "startOffset": 27505,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 20787,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 20786,
                    "startOffset": 20783
                }
            },
            "secId": "s0005",
            "sentence": "Today\u2019s estimates suggest that over 500,000 women are diagnosed with cervical cancer every year(y) and more than 260,000 die from the disease [1].",
            "startOffset": 20641,
            "title": "Introduction"
        },
        {
            "endOffset": 30974,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Frequencies of HPV-16 and -18-specific memory B- and T-lymphocytes at each time point were summarized for each group using descriptive statistics.",
            "startOffset": 30828,
            "title": "Statistical methods"
        },
        {
            "endOffset": 38699,
            "parents": [],
            "refoffsets": {
                "b0195": {
                    "endOffset": 38698,
                    "startOffset": 38694
                }
            },
            "secId": "s0075",
            "sentence": "This observation from clinical trials was also made in the context of organized vaccination programs [39].",
            "startOffset": 38593,
            "title": "Discussion"
        },
        {
            "endOffset": 33389,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Similar results were shown for the comparison of 2D AS04-HPV-16/18 and 3D 4vHPV with antibody titers that were more than two and fourfold higher for anti-HPV-16 (2.30) and anti-HPV-18 (4.14), respectively, with AS04-HPV-16/18 (Table 2).",
            "startOffset": 33153,
            "title": "Immunological non-inferiority and superiority"
        },
        {
            "endOffset": 24572,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Informed consent was obtained from subjects and their parents or legal guardians.",
            "startOffset": 24491,
            "title": "Study participants"
        },
        {
            "endOffset": 32475,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Compliance with the planned vaccination schedule was high (\u226595% in each group).",
            "startOffset": 32396,
            "title": "Study population"
        },
        {
            "endOffset": 24490,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Healthy girls aged 9-14y were eligible to participate as per the protocol requirements.",
            "startOffset": 24403,
            "title": "Study participants"
        },
        {
            "endOffset": 27890,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Cells were then stained with CD3, CD4 and CD8 antibodies, fixed and permeabilized, and further stained with antibodies specific for immune markers [CD40L, interleukin (IL) 2, tumor necrosis factor (TNF\u03b1) and interferon-gamma (IFN\u03b3)].",
            "startOffset": 27657,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 35148,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Similar results were observed at M36 in the TVC regardless of the baseline serostatus (Table 2 C).",
            "startOffset": 35050,
            "title": "Antibody responses"
        },
        {
            "endOffset": 38411,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 38410,
                    "startOffset": 38398
                },
                "b0090": {
                    "endOffset": 38410,
                    "startOffset": 38398
                },
                "b0185": {
                    "endOffset": 38410,
                    "startOffset": 38398
                },
                "b0190": {
                    "endOffset": 38410,
                    "startOffset": 38398
                }
            },
            "secId": "s0075",
            "sentence": "Our findings of higher antibody responses in girls vaccinated with 2D AS04-HPV-16/18 vaccine are in agreement with previous head-to-head comparisons between the AS04-HPV-16/18 and 3D 4vHPV vaccines; and results were consistent across studies in both young girls (2/3D) and adult women (3D) [1,18,37,38].",
            "startOffset": 38108,
            "title": "Discussion"
        },
        {
            "endOffset": 23067,
            "parents": [],
            "secId": "s0005",
            "sentence": "The comparison of the immunogenicity elicited by the reduced schedule of Cervarix compared to both 2D and 3D of Gardasil vaccines was therefore warranted in the HPV na\u00efve population targeted by mass vaccination programs where the duration of protection is of paramount importance.",
            "startOffset": 22787,
            "title": "Introduction"
        },
        {
            "endOffset": 31649,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "The plateau phase observed in the efficacy studies HPV-001/007/023 corresponds to GMTs in subjects for which vaccine efficacy was demonstrated.",
            "startOffset": 31506,
            "title": "Statistical methods"
        },
        {
            "endOffset": 37898,
            "parents": [],
            "secId": "s0075",
            "sentence": "In order to exclude a potential assay-related bias in favour of the AS04-HPV-16/18 vaccine, results were also confirmed using vaccine-independent PBNA.",
            "startOffset": 37747,
            "title": "Discussion"
        },
        {
            "endOffset": 31914,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Safety data were summarized descriptively in the TVC.",
            "startOffset": 31861,
            "title": "Statistical methods"
        },
        {
            "endOffset": 42600,
            "parents": [],
            "secId": "s0080",
            "sentence": "Cervarix is a trademark of the GSK group of companies.",
            "startOffset": 42546,
            "title": "Trademarks"
        },
        {
            "endOffset": 35049,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Antibody titers with the 2D AS04-HPV-16/18 remained well above the plateau for both antigens.",
            "startOffset": 34956,
            "title": "Antibody responses"
        },
        {
            "endOffset": 27073,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "refoffsets": {
                "b0005": {
                    "endOffset": 27005,
                    "startOffset": 26999
                },
                "b0125": {
                    "endOffset": 27005,
                    "startOffset": 26999
                }
            },
            "secId": "s0030",
            "sentence": "Polyvinylidene difluoride plates were coated with either an antibody specific for human immunoglobulins) or with L1 VLP antigens present in the AS04-HPV-16/18 vaccine [1,25] to quantify total or antigen specific memory B-cells, respectively.",
            "startOffset": 26832,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 25160,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Batch numbers of vaccine lots were AHPVA144B, AHPVA133C, AHPVA133E, AHPVA151C, AHPVA133A and AHPVA184C for AS04-HPV-16/18; NP39130, and H006966 for 4vHPV; and PHPVA012A for placebo vaccine.",
            "startOffset": 24971,
            "title": "Vaccines, randomization and masking"
        },
        {
            "endOffset": 30095,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Objectives were assessed sequentially.",
            "startOffset": 30057,
            "title": "Statistical methods"
        },
        {
            "endOffset": 39555,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 39554,
                    "startOffset": 39548
                },
                "b0155": {
                    "endOffset": 39554,
                    "startOffset": 39548
                }
            },
            "secId": "s0075",
            "sentence": "In our study, all 3 vaccine regimens induced HPV-16 and -18 antibody titers that were higher than the levels of naturally-acquired antibodies previously observed in women who had cleared a natural infection [1,31].",
            "startOffset": 39341,
            "title": "Discussion"
        },
        {
            "endOffset": 31794,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "The plateau level is not used as a correlate of protection but is informative and serves as a benchmark for studies with AS04-HPV-16/18 vaccine.",
            "startOffset": 31650,
            "title": "Statistical methods"
        },
        {
            "endOffset": 40339,
            "parents": [],
            "secId": "s0075",
            "sentence": "The clinical relevance of this observation is not known, although the magnitude of vaccine-induced antibody titers may influence persistence of immunity.",
            "startOffset": 40186,
            "title": "Discussion"
        },
        {
            "endOffset": 42342,
            "parents": [],
            "secId": "s0075",
            "sentence": "In summary, this study demonstrated that the 2D AS04-HPV-16/18 vaccine elicited superior antibody responses in girls aged 9 to 14y to those elicited by 2D and 3D 4vHPV vaccine up to M36.",
            "startOffset": 42156,
            "title": "Discussion"
        },
        {
            "endOffset": 31505,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "refoffsets": {
                "b0005": {
                    "endOffset": 31360,
                    "startOffset": 31354
                },
                "b0040": {
                    "endOffset": 31504,
                    "startOffset": 31501
                },
                "b0155": {
                    "endOffset": 31360,
                    "startOffset": 31354
                }
            },
            "secId": "s0040",
            "sentence": "Descriptive comparisons were made between anti-HPV-16/-18 GMTs in this trial and historical data, i.e. in women aged 15-25y (by ELISA) or 18-45y (by PBNA) who had cleared a natural infection and mounted an immune response [1,31] and GMTs (by ELISA) from the plateau phase (M45-50) of a long-term efficacy study in 15-to-25-year-old women vaccinated with AS04-HPV-16/18 [8].",
            "startOffset": 31132,
            "title": "Statistical methods"
        },
        {
            "endOffset": 35320,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Neutralizing antibody titers were found to be more than two and sixfold higher for HPV-16 and HPV-18 in the AS04-HPV-16/18 vaccine group vs. the 4vHPV groups, respectively.",
            "startOffset": 35148,
            "title": "Antibody responses"
        },
        {
            "endOffset": 40746,
            "parents": [],
            "secId": "s0075",
            "sentence": "Our trial was not powered to make statistical comparisons for CMI and descriptive analyses showed large overlaps in CMI responses between groups.",
            "startOffset": 40601,
            "title": "Discussion"
        },
        {
            "endOffset": 38925,
            "parents": [],
            "refoffsets": {
                "b0200": {
                    "endOffset": 38924,
                    "startOffset": 38920
                }
            },
            "secId": "s0075",
            "sentence": "The differences in immunogenicity between both HPV vaccines may in theory be due to different production methods and/or to the adjuvants used in each vaccine; available evidence supports an important role of the adjuvant [40].",
            "startOffset": 38699,
            "title": "Discussion"
        },
        {
            "endOffset": 29110,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "A more stringent according-to-protocol (ATP) analysis set was used for the primary analysis of non-inferiority comparisons.",
            "startOffset": 28987,
            "title": "Statistical methods"
        },
        {
            "endOffset": 31053,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Immunogenicity analyses focused on subjects who were seronegative at baseline.",
            "startOffset": 30975,
            "title": "Statistical methods"
        },
        {
            "endOffset": 39729,
            "parents": [],
            "refoffsets": {
                "b0080": {
                    "endOffset": 39728,
                    "startOffset": 39724
                }
            },
            "secId": "s0075",
            "sentence": "It has been hypothesized that this results of a better targeting or activation of lymph nodes cells by vaccines compared to mucosal infections and the use of adjuvants [16].",
            "startOffset": 39556,
            "title": "Discussion"
        },
        {
            "endOffset": 21674,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 21673,
                    "startOffset": 21670
                }
            },
            "secId": "s0005",
            "sentence": "In addition, the VLPs are manufactured by different methods [1].",
            "startOffset": 21610,
            "title": "Introduction"
        },
        {
            "endOffset": 34054,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "In the 4vHPV 2D and 3D groups, a proportion of subjects became seronegative during the course of the study, i.e. 13.9% with 2D 4vHPV and 7.2% with 3D 4vHPV.",
            "startOffset": 33898,
            "title": "Antibody responses"
        },
        {
            "endOffset": 24355,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Other secondary immunogenicity objectives included assessment of HPV-16/-18 neutralizing antibodies (by pseudovirion-based neutralisation assay (PBNA)) and frequencies of specific memory B and T cells.",
            "startOffset": 24154,
            "title": "Study design and ethics"
        },
        {
            "endOffset": 23727,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Protocol is summarized at www.gsk-clinicalstudyregister.com (GSK Study Identifier 115411).",
            "startOffset": 23637,
            "title": "Study design and ethics"
        },
        {
            "endOffset": 41987,
            "parents": [],
            "secId": "s0075",
            "sentence": "A strength of this descriptive study is that assessments were performed according to the same schedule and methodology in all groups, allowing a valid head-to-head comparison of immunogenicity.",
            "startOffset": 41794,
            "title": "Discussion"
        },
        {
            "endOffset": 23234,
            "parents": [],
            "secId": "s0005",
            "sentence": "This study was thus designed to assess immunogenicity and safety of a 2D schedule of the AS04-HPV-16/18 vaccine vs. 2D and 3D of the 4vHPV vaccine in girls aged 9-14y.",
            "startOffset": 23067,
            "title": "Introduction"
        },
        {
            "endOffset": 28401,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "The hierarchy of testing for immunological non-inferiority and superiority comparisons was pre-specified in the protocol.",
            "startOffset": 28280,
            "title": "Statistical methods"
        },
        {
            "endOffset": 35460,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "HPV-16/18-specific memory B cell- and CD4+ T cell-mediated responses were similar across all three groups (Fig. 3).",
            "startOffset": 35345,
            "title": "Cell-mediated immunity"
        },
        {
            "endOffset": 34855,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Titers remained above the plateau for HPV-16 in all groups, but fell below the threshold observed in Cervarix studies for HPV-18 antibodies in both 4vHPV groups (Fig. 2).",
            "startOffset": 34685,
            "title": "Antibody responses"
        },
        {
            "endOffset": 28145,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "refoffsets": {
                "b0145": {
                    "endOffset": 28144,
                    "startOffset": 28140
                }
            },
            "secId": "s0035",
            "sentence": "Reactogenicity and safety findings up to M12 were reported in a previous paper [29].",
            "startOffset": 28061,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 40185,
            "parents": [],
            "secId": "s0075",
            "sentence": "All groups were found to have antibody levels above the plateau for HPV-16, but for HPV-18 antibodies induced by 4vHPV were below the plateau benchmark with both dose schedules (Fig. 2).",
            "startOffset": 39999,
            "title": "Discussion"
        },
        {
            "endOffset": 22342,
            "parents": [],
            "refoffsets": {
                "b0070": {
                    "endOffset": 22341,
                    "startOffset": 22334
                },
                "b0075": {
                    "endOffset": 22341,
                    "startOffset": 22334
                }
            },
            "secId": "s0005",
            "sentence": "The high immune response to the AS04-HPV-16/18 vaccine observed in the adolescent population 9-14y of age led to the investigation and eventually to registration of 2-dose schedules (2D) in this age group in most countries [14,15].",
            "startOffset": 22111,
            "title": "Introduction"
        },
        {
            "endOffset": 33897,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "For HPV-18 antibodies, all subjects (100%) from the 2D AS04-HPV-16/18 group were still seroconverted at M36.",
            "startOffset": 33789,
            "title": "Antibody responses"
        },
        {
            "endOffset": 35996,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "Among them, only one non-serious pIMD (reactive arthritis) was considered by the investigator as possibly caused by vaccination and was related to the 4vHPV 2D group.",
            "startOffset": 35830,
            "title": "Safety"
        },
        {
            "endOffset": 31131,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Supplementary analyses were done by baseline serostatus and based on the TVC.",
            "startOffset": 31054,
            "title": "Statistical methods"
        },
        {
            "endOffset": 38592,
            "parents": [],
            "secId": "s0075",
            "sentence": "Immunological responses were found to be approximatively 2.3\u20132.8 and 3.5\u20136.8-fold higher in AS04-HPV-16/18 compared to 4vHPV groups (2D and 3D) for HPV-16 and HPV-18, respectively.",
            "startOffset": 38412,
            "title": "Discussion"
        },
        {
            "endOffset": 40965,
            "parents": [],
            "secId": "s0075",
            "sentence": "However, the median frequencies of HPV-16 and -18-specific memory B cells and CD4+ T cells at M7, M12 and M36 were numerically higher, though in the same range overall, for girls who received 2D AS04-HPV-16/18 vaccine.",
            "startOffset": 40747,
            "title": "Discussion"
        },
        {
            "endOffset": 36577,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "All SAEs resolved, except ulcerative colitis with relapse episodes, food-dependent exercise induced anaphylaxis, tension headache and juvenile idiopathic arthritis events, which were on-going at the time of the M36 database lock point.",
            "startOffset": 36342,
            "title": "Safety"
        },
        {
            "endOffset": 40600,
            "parents": [],
            "refoffsets": {
                "b0215": {
                    "endOffset": 40599,
                    "startOffset": 40592
                },
                "b0220": {
                    "endOffset": 40599,
                    "startOffset": 40592
                },
                "b0225": {
                    "endOffset": 40599,
                    "startOffset": 40592
                }
            },
            "secId": "s0075",
            "sentence": "The role of CMI in the control of HPV infections is not well established, although induction of antigen-specific memory B cells, a process in which CD4+ T cells play an essential role, is thought to be important for long-term vaccine-induced protection [43\u201345].",
            "startOffset": 40339,
            "title": "Discussion"
        },
        {
            "endOffset": 21874,
            "parents": [],
            "secId": "s0005",
            "sentence": "Inc).",
            "startOffset": 21869,
            "title": "Introduction"
        },
        {
            "endOffset": 22786,
            "parents": [],
            "secId": "s0005",
            "sentence": "Higher anti-HPV antibody titers have the potential to elicit a longer duration of protection.",
            "startOffset": 22693,
            "title": "Introduction"
        },
        {
            "endOffset": 24382,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Safety was also evaluated.",
            "startOffset": 24356,
            "title": "Study design and ethics"
        }
    ],
    "docId": "S0264410X17315980",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": "tfleung@cuhk.edu.hk",
                "first": "Ting Fan",
                "initial": "T.F.",
                "last": "Leung"
            },
            {
                "email": null,
                "first": "Anthony Pak Yin",
                "initial": "A.P.Y.",
                "last": "Liu"
            },
            {
                "email": null,
                "first": "Fong Seng",
                "initial": "F.S.",
                "last": "Lim"
            },
            {
                "email": null,
                "first": "Franck",
                "initial": "F.",
                "last": "Thollot"
            },
            {
                "email": null,
                "first": "Helen May Lin",
                "initial": "H.M.L.",
                "last": "Oh"
            },
            {
                "email": null,
                "first": "Bee Wah",
                "initial": "B.W.",
                "last": "Lee"
            },
            {
                "email": null,
                "first": "Lars",
                "initial": "L.",
                "last": "Rombo"
            },
            {
                "email": null,
                "first": "Ngiap Chuan",
                "initial": "N.C.",
                "last": "Tan"
            },
            {
                "email": null,
                "first": "Roman",
                "initial": "R.",
                "last": "Rouzier"
            },
            {
                "email": null,
                "first": "St\u00e9phanie",
                "initial": "S.",
                "last": "De Simoni"
            },
            {
                "email": null,
                "first": "Pemmaraju",
                "initial": "P.",
                "last": "Suryakiran"
            },
            {
                "email": null,
                "first": "Marjan",
                "initial": "M.",
                "last": "Hezareh"
            },
            {
                "email": null,
                "first": "Florence",
                "initial": "F.",
                "last": "Thomas"
            },
            {
                "email": null,
                "first": "Nicolas",
                "initial": "N.",
                "last": "Folschweiller"
            },
            {
                "email": null,
                "first": "Frank",
                "initial": "F.",
                "last": "Struyf"
            }
        ],
        "doi": "10.1016/j.vaccine.2017.11.034",
        "firstpage": "98",
        "issn": "0264410X",
        "keywords": [
            "Administration schedule",
            "Female adolescents",
            "Human papillomavirus vaccines",
            "Immunogenicity",
            "Safety"
        ],
        "lastpage": "106",
        "openaccess": "Full",
        "pub_year": 2018,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and 4vHPV vaccine administered according to two- or three-dose schedules in girls aged 9\u201314\u202fyears: Results to month 36 from a randomized trial"
    }
}